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The Human Immunodeficiency Virus Type-1 (HIV-1) is the causative agent of the
Acquired Immune Deficiency Syndrome (AIDS). Combination antiviral therapy has
proven to be particularly effective at suppressing viral replication, yet complete
eradication of the virus from an infected individual remains elusive. Recently, a new
class of antiviral drugs targeting the viral integrase (IN) has been added to the HAART
(high active antiretroviral therapy) regimen. This novel drug class exerts its inhibitory
effect by targeting one aspect of the dual-staged integration reaction. In contrast to the
other two viral targets of HAART, the reverse transcriptase (RT) and protease (PR)
enzymes, both of which have singular roles in viral replication, IN contributes a plurality
of functions to the viral life cycle, thus potentiating the development for further
therapeutic intervention. In spite of the intensity of investigation in the field, the
mechanistic details of several aspects of IN activity, especially of its ancillary functions
remain unclear. This thesis work focuses primarily on dissecting the contribution of the
carboxyl-terminal domain (CTD), in particular the terminal 18 amino acid ‘tail’ of this
domain, to both the primary integration activities and secondary functions of IN. This

was accomplished by conducting a survey of incremental deletions aimed at gradually
removing this region of the protein, and testing the resulting viruses in a number of
measurable assays of virologic function. In so doing we identified a number of
anomalous mutant phenotypes, the ensuing characterization of which should contribute to
better understanding the roles of IN with regard to both its primary and secondary
functions in the replicative strategy of HIV-1.
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CHAPTER 1- INTRODUCTION

Despite the recent incidence of HIV-1 as a human pathogen, it has, in the ensuing
two and a half decades since its inception, become one the most prominent public health
challenges in modern times, with current estimates of 30 million infected people
worldwide [1]. Without treatment, HIV-1 infection in the overwhelming majority of
cases progresses ultimately to AIDS, the end stage of disease in which the host’s
substantially ablated immune system renders the individual susceptible to a wide range of
opportunistic infections. Antiviral drugs that target and effectively inhibit viral
replication have proven to significantly curtail the disease progression and concomitantly
decrease HIV-1-associated mortality, but efforts to completely eradicate the virus from
the body has thus far been unsuccessful.
The IN protein has long been a much sought-after target for antiviral therapy. The
reaction that it catalyses, integration, has no counterpart to any known cellular processes,
thus increasing the likelihood of developing highly specific, well-tolerated drugs which
would block this viral activity. The development in recent years of compounds that
selectively target IN activity has successfully increased the repertoire of available
antiviral drugs, and proven an extremely valuable addition to the existing armamentarium
particularly to patients who are unresponsive to previous drug classes. These compounds,
chemically classified as diketo acids, inhibit viral replication by targeting the second step
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of the integration reaction, called strand transfer, and thus the designation of these drugs
as strand transfer inhibitors (STI).
The impetus to develop new drugs is ever present, however, as the genetic barrier
to drug resistance is low, requiring only one or two point mutations to confer resistance to
both developed IN inhibitors. In light of the highly specific targeting of the STIs, IN is
very likely amenable to inhibition by other routes. Indeed the initiation of strand transfer
is entirely dependent upon the completion of a prior catalytic step (3’ processing), thus
making the latter an equally attractive enzymatic target for directed IN inhibition.
In addition to its catalytic roles in proviral integration and establishment, IN
facilitates a number of secondary functions during the viral life cycle that include viral
assembly, the precision of particle formation, and the efficiency of reverse transcription
[2-8], each of which could present a future target for therapeutic intervention. Though
significant insights have been gained in the mechanistic details of the integration
reaction, relatively little is known of IN involvement in its secondary activities.
Efforts to elicit a high-resolution crystal structure of HIV-1 IN have thus far been
unsuccessful, but evidence gleaned from other lines of investigation indicate that IN
consists of three domains: an N-terminal domain (NTD), a catalytic core domain (CCD)
and a carboxyl-terminal domain (CTD). Each domain contributes in some fashion to the
mechanics of the integration itself, but it is apparent that the CTD is especially involved
in the facilitation of secondary functions. Indeed, mutagenic surveys of conserved
residues in the CTD revealed that the vast majority of IN mutants tested were defective
for viral functions that occur prior to integration, at or before reverse transcription or
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during the late stages of viral polyprotein processing and/or virion maturation and egress
[2].
It was recently discovered that the IN CTD is a potent target for p300-mediated
histone acetyltransferase (HAT) activity, targeting a cluster three lysine residues (Lys
264, 266, 273) for acetylation [3, 4]. Though we demonstrated that this post-translational
modification was not critical for viral propagation in a tissue culture infection model [4],
we endeavor to investigate this phenomenon further. The final 18 amino acids of the IN
CTD constitute a region of the domain that is recalcitrant to structural determination, due
its high levels of flexibility and molecular motion. This unstructured ‘tail’ encompasses
residues 271-288, and is reminiscent of the unstructured tails of the histone proteins
which themselves undergo extensive covalent modifications that modulate their various
activities [5]. In light of the multifunctional nature of IN, and the potential role of the
CTD to IN secondary functions, it was intriguing to find that the CTD is such a potent
target for covalent modifications, alterations that could feasibly modulate the enzyme’s
activity. To investigate this phenomenon, we created a sequential panel of truncated IN
mutants, with the aim of gradually removing the unstructured tail, and consequently the
residues targeted for modification, and observing the effect on a variety of measurable
viral processes.
We found that sequential and stepwise removal of residues resulted in a gradual
attenuation of infectivity up to residue 273 (IN 273), corresponding to a removal of
fifteen residues, and further shortening of the CTD resulted in a sudden loss of infectivity
(IN 272). Removal of the two successive residues, corresponding to truncation at IN 270
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and 271, still rendered these viruses noninfectious. However and remarkably, it was
discovered that removal the one more consecutive residue (D270), corresponding to a
truncation that includes IN R269, rescued viral infectivity. This thesis reports the
investigation of IN C-terminal truncations within a window of 28 residues (IN 260-288),
wherein these mutants are characterized and classified via a number of assays in order to
ascertain the contributions that the IN CTD makes to IN function, and in a broader sense
to HIV-1 replication itself. This information is not only of significant academic interest,
but of practical importance as well, for the potential development of combative agents
that more comprehensively inhibit one or more of the functions coordinated by IN during
the viral replicative cycle.
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Natural history of HIV-1
HIV-1 is a member of an extensive and diverse family of viruses called
retroviridae, enveloped diploid RNA viruses that are distinguished by the utilization of
two unique replicative strategies: reverse transcription of the RNA genome into linear,
double-stranded DNA, and the subsequent integration of this DNA into the host cell’s
chromosomal DNA. Prior to the discovery of HIV-1 as the etiological agent of AIDS in
1983, there was only one other retroviral infection known to cause disease in humans, the
Human T-cell Leukemia Virus (HTLV-1 and II). Initially, some scientists believed that
HIV-1 was a new strain of HTLV, and was nominally designated as HTLV III, but
subsequently, studies of virion morphology and genetic composition indicated that this
novel retrovirus (Lymphadenopathy Virus, LAV, 1983) was similar to a distinct
subgroup of retroviruses called the lentiviruses [6, 7]. Lentiviruses are so named as an
indicator of the characteristics of the disease they induce, a typically long incubation
period between initial infection and the onset of serious symptoms, and a chronic,
persistent infection (lentus, latin for ‘slow’). Lentiviruses are now known to infect a
number of non-human species, including horses (equine infectious anemia virus, EIAV),
goats (caprine arthritis-encephalitis virus, CAEV), sheep (Visna virus), cats (Feline
Immunodeficiency Virus, FIV), and monkeys (simian immunodeficiency virus, SIV), a
common feature of the diseases they bring about in their natural hosts being the loss of
function or killing of specific cells and tissues, even in the face of persistent and robust
immune responses. In the case of HIV-1, the major cell population targeted is the CD4+-
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helper T cells, an arm of immune system involved in cell-mediated immunity. The
gradual erosion of this cell population leads to the acquisition of AIDS.
In addition to the common clinical manifestations of the disease courses, the
lentiviruses share a characteristic virion morphology and genetic architecture. Under the
electron microscope, the mature lentiviral particle, or virion, is observed to contain a
cone-shaped core, a core shape unique to the lentivirus genus (Figure 1A). The core is
comprised of approximately 1500 molecules of the viral capsid (CA), whose innate selfassociative properties promote the formation of a lattice-like cage that encapsulates the
diploid RNA genome and other associated viral proteins. In the virion, the core itself lies
in a sequestered environment, the boundaries of which are defined by a lipid bilayer of
cellular plasma membrane origin, which assumes a typically spherical shape
approximately 100nm in diameter, and in which is embedded outwardly-projecting viral
envelope spikes.
The lentiviral genetic architecture is an additional defining characteristic of this
class of retrovirus. All retroviruses encode dedicated genes for the structural (Gag),
enzymatic (Pol) and envelope (Env) protein components of their viruses. ‘Simple’
retroviruses contain no more than this minimal genetic information, whereas ‘complex’
retroviruses, which include the lentiviruses, encode several other accessory proteins that
assist in various aspects of viral replication (Figure 1B). For HIV-1, these proteins
include two viral factors Tat and Rev (described in greater detail in ensuing sections),
which, by virtue of their absolute requirement for replication, are often precluded
descriptively from the status of ‘accessory’. The virus encodes three other accessory
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proteins: viral infectivity factor (Vif), viral protein R (Vpr), viral protein U (Vpu) and
negative factor (Nef), proteins that modulate several processes to provide the ideal
cellular environment for viral replication. These latter three products can more suitably
be described as accessory proteins, for in some in vitro tissue culture models of HIV-1
infection, viral propagation can proceed efficiently, and in some cases more proficiently,
in their absence. The dispensability of these accessory proteins does not however extend
to in vivo infections, wherein the actions of some of these proteins become more
essential. Overall, the accessory genes of the complex retroviruses confer a level of
control over viral replication beyond that of their simple retrovirus counterparts, and are
believed to in part account for some of the clinical manifestations and/or outcomes of
infection.
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Figure 1. Structure of HIV-1 virion and genetic organization. A) Diagrammatic crosssectional representations of the architecture of the immature and mature forms of the
HIV-1 virion are displayed alongside electron micrographs of the corresponding forms.
Virions produced just after budding conform to the immature form, and require the
activation of the viral PR to induce maturation, in which the viral precursor are cleaved
into the constituent components and condense to produce the canonical cone-shaped core
characteristic of the lentiviruses. B) Schematic of the genetic architecture of HIV-1, an
example of a complex retrovirus, containing addition ORFs for the expression of various
accessory proteins. The vertical displacement of the coding regions indicates the location
in disparate reading frames. The splice sites that accommodate the expression of the Vif,
Vpr, Tat, Rev, Vpu, Env and Nef from processing of the full-length mRNA are shown
below. (Adapted from [8])
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HIV-1 Replication Strategy
From the onset of infection and throughout the remaining lifetime of the host,
infection by HIV-1 is characterized by persistent and robust viral replication, despite the
presence of often potent host immune responses. HIV-1 is capable of infecting several
cell types, including macrophages, dendritic cells, nervous system cells, and some
epithelial cells, but the main reservoir for viral replication is primarily within the CD4+
helper T lymphocyte cell population. In vivo estimates from mathematical models of viral
replication dynamics indicate that the life cycle is on average 1.2 days long [9], and
results of different studies have placed the burst size, or the number of virions produced
throughout the lifetime of one infected cell, from numbers ranging from 0.92x103 to
5.5x104 virions [10-13].
The HIV-1 life cycle (Figure 2) can be bifurcated into early and late stages. The early
stage entails events that occur when a susceptible cell first encounters a viral particle, or
virion, and encompasses the events of viral entry, the ensuing reverse transcription of
viral RNA as the viral core traverses the cytoplasm en route to the nucleus, and
culminating in the formation of the integrated viral DNA (provirus). The subsequent late
stage encompasses the program of proviral gene transcription and translation, and the
assembly of viral components for the eventual release of progeny virus, and their
subsequent maturation. Throughout this dissertation, this designation of early and late life
cycle events is used to describe the phenotypic manifestation of HIV-1 mutants, the viral
mutant phenotype described as being blocked in the early or late stages of replication.
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Figure 2. The HIV-1 life cycle. The early events of the viral life cycle begin with viral
entry, and end with the establishment of the integrated provirus. The late events entail the
program of viral gene transcription and protein translation that ultimately conclude with
the production of new viral particles that begin the infection cycle anew. (Adapted from
[14])
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Late stage of virus replication:
Viral gene transcription and translationThe establishment of the provirus in the host genome demarks the boundary
between early and late virus life cycle events. As mentioned, the late stage encompasses
the transcriptional and translational program of viral gene expression that culminates
ultimately in the release of progeny virus that will begin the infection cycle anew. The
organization of the HIV-1 genome as it exists in the viral RNA and proviral DNA forms
are depicted in Figure 3 below.

5’ Cap

Viral RNA
R

U3

R

U3

R

AAA 3’

Reverse transcription

Provirus
U3

R

Figure 3. Viral genome in RNA and DNA forms. The process of reverse transcription
creates the long terminal repeats, or LTRs, at both ends of the provirus form. This
positions the transcriptional promoter and enhancer elements at the 5’ end, and poly-A
signals at the 3’ end. R: Terminal direct repeat RNA; U5: Unique regulatory sequences at
the 5’ end; U3 Unique regulatory sequences at the 3’ end.

The long terminal repeats, or LTRs, are direct repeat sequences that flank the
proviral genome, and are formed as a consequence of the reverse transcription process

- 12 -

(described below). The upstream or 5’ LTR contains transcriptional enhancer and
promoter elements that recruit the host transcriptional machinery, and the downstream or
3’ LTR contains poly-A addition signals for transcription termination and for
posttranscriptional mRNA processing. The integration of the viral genome into that of the
host cell makes the viral DNA indistinguishable from that of chromosomal genes, and as
such the provirus is transcribed by the host’s RNA polymerase II machinery.
The HIV-1 transcriptional program is an intricate process entailing a biphasic
scheme of ‘early’ and ‘late’ proviral gene expression, not to be confused with the
terminology used above to describe the two stages of the viral life cycle. The
transcriptional scheme helps overcome two obstacles to proviral gene expression. The
initial encountered barrier is the inherent inefficiency of the viral LTR to elongate the
transcriptional unit [15]. In the absence of the specific regulatory viral transactivator
protein (Tat), RNA polymerase II complex efficiently initiates transcription from the
LTR, but then frequently pauses and disengages the DNA template soon after initiation,
producing predominantly short, abortive transcripts [15]. To circumvent this but prior to
Tat synthesis, basal levels of LTR activity permit the formation of low levels of fulllength viral transcript, which are spliced to completion to a number of distinct iterations,
determined by the utilization of different pair-wise combinations of 5’ and 3’ splice sites
on the viral transcript. Three viral proteins, the early gene products, are translated from
these fully-spliced transcripts: Tat, Rev and Nef (negative factor). Tat is targeted to the
nucleus via an embedded nuclear localization sequence (NLS) [16, 17], where it binds to
its cognate transactivator response element (TAR), a 59 bp stem-loop RNA structure
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specified within the untranslated U5 region of the viral mRNA transcript [18-20]. Tat
binding recruits several host proteins to the TAR element, the end result of which is the
hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA
polymerase II, which greatly enhances its processivity on the proviral DNA template
[reviewed in [21]] . In the presence of Tat, it has been estimated that the transcriptional
activity of the LTR is enhanced by a factor ranging from hundreds to thousands of fold.
The Tat circuitry establishes a positive feed-back loop that drives high level production
of fully-spliced viral RNA transcripts, thus quickly increasing the levels of the early gene
products (Tat, Rev and Nef) and completing the early phase of proviral transcription.
The second control point exists for the expression of the ‘late’ gene products, the
structural and accessory proteins: Gag, Pol, Vif, Vpr, Vpu and Env. This nexus has its
basis in the fact that only fully-spliced, intron-free mRNAs can be ushered into the
cytoplasm to be translated. The viral proteins are however encoded by transcripts which
contain signals (5’ and 3’ splice sites and somewhat ill-defined RNA structural elements)
that actively retain and in some cases promote the decay of these RNAs within the
nuclear compartment [22-24]. To switch on the expression of the late viral genes, the
virus relies on the accumulation of the early gene product, Rev. In effect, Rev is required
to promote the transport of the late mRNAs into the cytoplasm where they can be
translated. However, Rev must attain a sufficiently high nuclear concentration before
cooperative and functional binding by at least 8 Rev molecules to an intricate RNA
structure located within the env gene, the Rev-responsive element (RRE) [25-27]. The
RRE is found in full-length and partially spliced viral transcripts (Figure 1B), and Rev-
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binding facilitates the active transport of these transcripts out of the nucleus and promotes
their cytoplasmic accumulation and at later stages, full-length viral genomic RNA makes
it to the plasma membrane where it is packaged into new virions. The partially spliced
mRNA species contain ORFs for the accessory proteins Vif (virus infectivity factor), Vpr
(viral protein R), Vpu (viral protein U) and the envelope protein (Env), whereas the fulllength unspliced transcripts directs the expression of the Gag and Gag-Pol polyprotein
precursors.

AssemblyThe gag gene encodes the 55kD precursor protein (Pr55Gag), a conglomerate of
the main structural proteins of the virion. The precursor is cleaved during or just after
virus by the viral protease into its constituent parts: matrix (MA p17), capsid (CA p24),
nucleocapsid (NC p7), and p6, each of which, with the exception of p6, has its individual
role within the viral particle itself. Prior to budding, however, the Gag precursor
polyprotein is the minimal viral component required for directing the assembly and
release of virus particles. Indeed, exogenous expression of Gag, in the absence of all
other viral constituents, is sufficient to assemble the production of virus-like particles
(VLPs) [28-30]. A co-translational modification that appends a myristic acid moiety to
the N-terminal MA domain directs precursor protein-plasma membrane association, and
facilitates the intimate involvement of Gag with the membrane’s inner leaflet as viral
components are assembled and budding commences [31]. The Gag p6 domain, located at
the carboxyl-terminus of the precursor, contains a short amino acid motif (Pro-Thr-Ala-
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Pro [PTAP]) known as a late domain, which interacts with components of the machinery
that comprise the multivesicular body pathway that normally recycles vesicles in the
endosomal membrane system [32, 33]. HIV-1 usurps the components of this pathway for
its own ends, the assembling Gag polyproteins inducing outward membrane curvature,
whilst host protein constituents of the multivesicular pathway subsequently accommodate
pinching off of nascent particles from the cell surface.
The pol gene encodes the enzymatic viral proteins [viral protease (PR p10),
reverse transcriptase (RT p66/p55) and integrase (IN p32)] which are co-packaged into
virions in the context of the large Gag-Pol precursor polyprotein (Pr160Gag-Pol). The
translation of both the Gag and Gag-Pol precursors are derived from the same transcript,
the virus utilizing a unique method of accessing the pol ORF, which is encoded in the
third reading frame of the mRNA transcript relative to the gag sequence. During
translation of the viral transcript, the ribosome encounters a ‘slippery’ sequence, a string
of consecutive uracil residues. This ‘slippery’ sequence, in combination with a nearby
downstream RNA secondary structure, causes the ribosome to momentarily pause
translation and slip back a single nucleotide on the mRNA before recommencing
translation, thus shifting into the pol ORF, and translating the Pol products [34, 35]. The
pol gene is thus translated as Gag/Pol fusion protein with the majority of the Gag protein
appended at the N-terminus of the Gag-Pol precursor. Ribosome slipping occurs
approximately 5% of the time, thus accounting for the ratio of 1 Gag-Pol precursor for
every 20 Gag precursors found in the cell and subsequently in the virion. This delicate
balance of Gag to Gag-Pol product is important for precision of virus assembly, for it has
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been shown that overexpression of Gag-Pol can inhibit virion production [36]. The GagPol precursor, as it contains Gag sequences at the N-terminus can consequently be
myristylated, and intermolecular interactions between the shared Gag domains of the
Pr55Gag and Pr160Gag-Pol are believed in part to direct the Gag-Pol fusion protein to
assembling virions [37, 38].
The envelope protein (Env) is translated as a 160kD precursor by the protein
translation machinery of the rough endoplasmic reticulum (ER), which directs the protein
into the secretory pathway for its eventual delivery to the cell plasma membrane. During
its egress through the membranous compartments of the ER and Golgi apparatus, the
protein is extensively glycosylated, and at some point is cleaved by host proteases into
the final gp41 and gp120 components of the mature envelope protein [39, 40]. gp41 is the
portion of envelope that is imbedded in the plasma membrane, and is referred to as the
transmembrane (TM) component of the envelope. The gp120, referred to as the surface
(SU) env segment, lies on the cell exterior, and subsequently the outside of the virion,
and remains associated with gp41 via non-covalent interactions. Once deposited on the
plasma membrane, env diffuses laterally across the plasma membrane and interacts with
assembling Gag precursors on the inner leaflet of the plasma membrane. On the virion,
the viral Env assumes a trimeric formation, and determines the viral tropism, facilitating
entry into select target cells that bear the required receptors that can engage the specific
class of HIV-1 envelope protein encountered.
The final significant viral component, the RNA genome, is packaged at a quantity
of two positive-sense strands per particle. These RNA molecules are post-
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transcriptionally modified as natural host mRNA transcripts, with a 5’ cap and an
appended 3’ poly-A tail. The packaging signal, or psi element (), an extensive RNA
secondary structural element specified at the 5’ end of the viral transcript, mediates the
association of the genomic RNA with the NC domain in the Gag precursor at the plasma
membrane [41-43].

Budding and MaturationAs the Gag and Gag-Pol precursor polyproteins assemble on the inner surface of
the plasma membrane, membrane curvature is induced by Gag multimerization on the
inner surface of the plasma membrane. Viral particles bud from the plasma membrane of
the cell, a process that requires the activity of the viral protein U (Vpu) [44-46]. The
virion, as it is released, is in an ‘immature’ form, and is morphologically distinguishable
from the mature particle counterpart. Immature particles are observed under the electron
microscope as possessing an electron-dense cloud of material just on the inner portion of
the membrane, which is presumptively the closely-packed, membrane-associated
precursor proteins, and an electron-lucent center (Figure 1A). Maturation of the virion
coincides with the activation of the viral protease (PR), which cleaves the precursor
proteins into the constituent, mature proteins. The timing of protease activity needs to be
precise; premature activation, as observed in some IN mutants, releases mature viral
proteins into the cytoplasm and prevents their packaging into virions [47, 48].
Furthermore, since virion assembly requires the domain activities of the extreme N- and
C-termini of the intact Gag precursor, premature proteolytic cleavage also interferes with
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virion assembly. The mechanism of the switch that controls PR activation is not wellunderstood, but it is apparent that Gag-Pol dimerization is a prerequisite [49]. The
sequestered environment of the virion is thought to increase the precursor protein
concentration in the immediate environment, which in turn promotes the dimerization
leading to PR self-cleavage, and the inexorable processing of the surrounding precursors.
The cleaved CA proteins from the precursors condense to assume the characteristic coneshaped viral core, in which is enclosed the viral RNA and other viral cleavage products
including RT and IN. The RNA itself maintains an association with NC protein, which
contributes a protective effect on the viral genome. The free MA domain remains
associated with the plasma membrane, and provides support for the virion superstructure
[50]. The mature virion is now infectious and capable of perpetuating the viral life cycle
by infecting a new cell.

Early stage of virus replication:
EntryHIV-1 preferentially replicates in CD4+ T cells, but will enter any cell, human or
otherwise, that expresses on its cell surface the required receptors. The viral glycoprotein
envelope that decorates the surface of the virion is the determinant of host range and cell
tropism, as appropriate and specific engagement with uniquely expressed cell surface
receptors on the target cell is a prerequisite for activating the membrane fusogenic
activity of the envelope [51-54]. HIV-1 entry is dependent on interactions between the
envelope protein and two distinct receptors on the cell surface. One receptor is invariably

- 19 -

the CD4 glycoprotein, and it is to this that the initial binding occurs with the gp120 SU
subunit of Env. This results in a conformational change in gp120 that facilitates its
binding to its required co-receptor, which can be either the CXCR4 and CCR5 chemokine
receptor. These chemokine receptors are multipass membrane-spanning proteins involved
in G-protein signaling [55, 56], and in vivo, are expressed on defined and distinct cell
populations. The envelope protein is usually able to engage only one or the other coreceptor, the determinants for co-receptor utilization lying in the variable loop 3 (VL3)
segment of the gp120 subunit [57]. Since CXCR4 is co-expressed with CD4+ mostly in
T-helper cells, viruses that utilize the CXCR4 receptor are called T-tropic viruses. CCR5
is expressed with CD4 on both CD4+ T cells and macrophage. Viruses using CCR5 as a
co-receptor for entry were originally classified as M-tropic viruses.
After engagement of the envelope with the receptor and co-receptor, structural
rearrangements of the gp120 subunit activate the gp41 TM subunit, which contains a
fusion peptide. In the context of the unengaged envelope the fusion peptide sequence is
buried within the trimeric structure. However, upon receptor binding, internal molecular
rearrangement of gp41 SU results in the insertion of the fusion peptide into the cellular
membrane, an action that juxtaposes the viral and cellular membranes. The two
membranes fuse, uniting the intravirion and intracellular compartments, and the viral core
is ushered into the host cell’s cytoplasm.
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Reverse TranscriptionAfter entry, certain components of the macromolecular complex of the viral core
disassemble in a little-understood process called uncoating, leaving the viral RNA in
complex with a subset of the original core proteins in the cytoplasm, or just outside the
nuclear envelope. This ribonucleoprotein complex is called the reverse transcription
complex (RTC) or preintegration complex (PIC), and it is in this context that the program
of reverse transcription occurs [58]. The PIC is believed to contain the viral RT, IN, NC,
Vpr, and other associated host proteins, but an accurate depiction of its components is
lacking.
RT is an RNA- and DNA-dependent polymerase, and functions as a heterodimer
of two related subunits, the p66 and p51 subunits. The p66 subunit contains the RT
domain, and an RNaseH domain appended at the C-terminus. The p51 subunit is derived
from the p66 subunit, but with the RNaseH domain removed by HIV-1 protease action.
This latter subunit does not contribute any catalytic activity, but instead appears to
contribute a structural role for the assembled heterodimer [59]. A tRNA molecule that is
selectively packaged in the virion, tRNA3Lys [60], hybridizes with a complementary
sequence on the genomic RNA close to the 5’ end called the primer binding site (PBS),
and primes the initial synthesis of minus-strand DNA, which extends to the 5’ end of the
molecule [61]. This initial synthesized DNA is called minus-strand strong stop DNA, and
contains a sequence found at both the 5’ and 3’ ends of the viral RNA called repeat (R)
sequences that are direct repeats of each other. The RNaseH domain of RT digests the
RNA in the RNA-DNA hybrid, and frees the minus-strand strong stop DNA to hybridize
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with the R sequence at the 3’ end of the genome. This template switching is called strand
transfer (not to be confused with IN strand transfer), and is the first of two such events to
occur during reverse transcription.
After the strand transfer, minus-strand DNA synthesis proceeds from the 3’end,
with the RNaseH domain of RT again digesting the RNA in the lengthening hybrid as
elongation occurs. Certain purine rich regions of the genomic RNA, one located at the 3’
end of the genome (3’ polypurine tract or 3’ PPT) and another close to the center of the
genome within the IN region (central polypurine tract or cPPT), are less-susceptible to
RNaseH digestion however, and as the minus-strand synthesis proceeds, the RNA in
these regions persist and serve as primers for the synthesis of plus-strand DNA in the
opposite direction. The first plus-strand DNA synthesized terminates at the PBS sequence
on the minus-strand strong-stop DNA from the first strand transfer jump, and is called
plus-strand strong-stop DNA. The plus-strand strong-stop DNA then facilitates the
second strand transfer event, hybridizing with the PBS at the 5’ end. Elongation then
proceeds in both directions from both DNA strands, resulting in the formation of the long
terminal repeats (LTRs), and the double-stranded cDNA, which is the substrate for the
viral IN. Reverse transcription is an error-prone process, since RT possesses no proofreading activity, and accounts partly for the high mutagenic rate of the virus. It is
estimated that the mutation rate is on the order of 3 × 10−5 to 4 × 10−5 mutations per
target base pair per cycle [62, 63].
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Nuclear translocation and integration:
The lentiviruses, such as HIV-1, are unique in the regard that they are fully
capable of infecting terminally differentiated, non-dividing cells, or cells that are arrested
in the cell cycle [64-66]. Since integration of the viral genome by necessity requires the
juxtaposition of viral components and the chromosomal DNA, the permanently intact
nuclear membrane in these cellular targets presents a natural barrier to the cellular DNA.
Indeed, some retroviral infections, for example those of Moloney murine leukemia virus
(Mo-MuLV) and Rous sarcoma virus (RSV) are dependent on the progression of the cell
cycle into mitosis, wherein the dissolution of the nuclear membrane provides access to
the cellular DNA [67-69]). HIV-1 in contrast is known to productively infect terminally
differentiated macrophage and dendritic cells. The HIV-1 PIC engages components of the
nuclear pore complex (NPC), a protein-lined channel that spans the nuclear double
membrane, which regulates the bi-directional molecular traffic between the cytoplasm
and nucleoplasm, and can be transported in an energy-dependent manner into the nucleus
[70] . It is currently a matter of intense debate as to the specific determinants in the PIC
that facilitate its transport into the nucleus. Nuclear localization signals (NLS) have been
found in Vpr [71], IN [72], and MA [73] proteins, and there are even some implications
that a central DNA flap [74], which is a portion of overlapping DNA sequence created at
the cPPT during reverse transcription, could facilitate nuclear entry. Whichever may be
the case, it is clear however that the macromolecular deoxyribonucleoprotein complex
constituting the PIC exceeds the upper limit (50kDa) for passive diffusion through the
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nuclear pore [58], and thus depends on active facilitated transport mechanisms to get it or
parts thereof into the nucleus.
The integration reaction will be described in more detail in further sections, but a
brief overview will be given here. The integration reaction itself is divided into two
sequential and spatially separated reactions, the first of which putatively occurs in the
cytoplasm upon completion of reverse transcription. This reaction, called 3’ processing,
proceeds with IN recognition and binding of the viral cDNA ends, and the removal of a
terminal dinucleotide from the 3’ end of both DNA strands. This activates the DNA ends
for the subsequent strand transfer step, which occurs once the PIC has traversed the
nuclear pore. Here, IN covalently links the recessed 3’ DNA ends to the chromosomal
DNA in a concerted cleavage-ligation reaction. The immediate product is the viral DNA
covalently linked at both 3’ends, but with a 5 bp stretch of unpaired bases flanking the
site of insertion. Host DNA repair enzymes are then believed to fill in the unpaired gaps
at either end of the insertion. The viral genome thus becomes contiguous with and
undistinguishable from cellular genes, and can be transcribed by the cellular RNA
polymerase II machinery. Though integration can potentially occur anywhere in the
genome, HIV-1 exhibits a predeliction to integrate in chromosomal regions where genes
are actively transcribed, where the decondensed chromatin structure of the immediate
environment is more conducive to efficient gene transcription.
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Alternative fates of viral DNA:
Integration of viral cDNA into chromosomal DNA is an essential step in the
retrovirus life cycle, and is considered to be the natural fate of the newly reversetranscribed DNA product. Integration is, however, only one of several fates for viral
DNA. Even in wild-type (WT) viral infection, significant levels of unintegrated linear
and circular viral DNA forms can be detected [75-77]. The circular forms contain either
one or two copies of the viral LTRs, and are called 1-LTR and 2-LTR circles respectively
(Figure 4). The mechanism by which 1-LTR circles are produced is uncertain, but they
are believed to be either the product of errors incurred during the reverse transcription
reaction [78, 79], or created by homologous recombination between the two LTRs after
nuclear entry [80, 81]. 2-LTR circles are purportedly produced by the action of resident
nuclear DNA ligases that join the free blunt-ended viral DNA ends together [82]. Since
ligation activity is localized to the nuclear compartment, the formation of 2-LTR circles
is often used as a surrogate marker for the successful nuclear import of viral DNA.
Quantification of 2-LTR circles is also used as an in vivo measure of the catalytic
efficiency of IN mutants. IN mutants deficient for integration catalytic activity, which
includes the initial processing of the viral DNA ends, produce a preponderance of bluntended viral DNA species, an ideal substrate for blunt-ended DNA ligation to produce
high levels of 2-LTR species. The 1- and 2-LTR DNAs are considered dead-end viral
DNA products of reverse transcription, for the transcriptional activity from these species
is very limited, and, possessed of no other means of replicating, they are eventually
diluted out of replicating cell cultures after several rounds of cell division. In non-
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replicating cells they are quite stable, however, as circular DNA forms can be detected in
infected macrophage cultures up to 30 days post infection [83]. The role, if any, of these
circular forms in HIV-1 pathogenesis is still uncertain.

Cytoplasm

Cytoplasm

or

or

Nuclear envelope

Undefined nuclear
host factors and
lack of integrase
Circularization

Circularization

2-LTR
2-LTR

1-LTR

?
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Nucleus

Figure 4. Alternative fate of viral DNA. Reverse-transcribed viral cDNA is the required
precursor of the integrated provirus, but in the absence of IN catalysis, circular products
containing one or two copies of the viral LTR sequences (1- and 2-LTR circles
respectively) accumulate in the nucleus. Since 2 LTR circles are contingent upon nuclear
ligases for their formation, their presence is indicative of successful nuclear import of
viral cDNA.
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Roles of Accessory Viral Genes:
The preceding overview of the HIV-1 life cycle describes only the minimal
processes required for the viral replication program. In many in vitro infection models
using immortalized cell lines, these processes are sufficient for viral replication, and in
such circumstances the accessory proteins Vif, Vpr, Vpu and Nef are dispensable. In vivo
replication, however, presents several challenges to the virus not encountered in vitro,
and it is here that the actions of most of the accessory proteins are required to surmount
these host-mediated barriers to replication. A comprehensive review of these accessory
proteins will not be provided here, but their basic functions will be outlined [for general
review see [84]]. This will provide a framework for understanding the selection of certain
genetic backgrounds used for specific assays, in which the activity of an accessory gene
can be detrimental for the purposes of the particular assay measurement.

NefNef is one of the early viral gene products, expressed in abundance soon after
establishment of the proviral DNA. The protein is a small (25 kDa) membrane-associated
protein, utilizing an attached myristylic acid to anchor its N-terminus into the plasma
membrane. Though Nef has been attributed with a multitude of functions, including
enhancement of virion infectivity [85], inhibition of the apoptosis [86], and up-regulation
of specific surface markers on distinct cells [87], the most recognized ones are the
downregulation of CD4 and MHC-class I molecule on the cell surface [88, 89]. The
removal of CD4 molecules from the cell surface increases the efficiency of viral release
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as CD4 can interact with the viral envelope on coalescing virions on the cell surface [90].
MHC-I downregulation functions as a means of evading immune system surveillance by
cytotoxic T lymphocytes (CTL), which scan the surfaces of cells for the presence of
foreign peptides which are loaded onto MHC-1 molecules. These activities are obviously
not required in the tissue culture dish, and the dispensability of Nef in combination with
the propitious location of its ORF at the end of the genome, where there is little overlap
with other protein ORFs, make this region of the very compact HIV-1 genome amenable
to genetic manipulation. The insertion of genetic markers such as GFP or drug resistance
markers into the readily replaceable nef gene is commonly used as an investigative tool
for tracking viral infectivity and gene expression.

VifThe major function of Vif is to subvert an innate cellular antiviral activity which
is mediated by APOBEC3G/F. APOBEC3G/F are cytidine deaminases, found usually in
the cytoplasm [For review see [91, 92]] . In cells that are productively infected with HIV1, APOBEC3s are packaged with the outgoing virion, remaining associated with the core
components as a new cell is infected. The antiviral activity of APOBEC3G/F is
manifested during reverse transcription, wherein they potently deaminate cytidine
residues on the minus-stranded DNA, leading to the significant accrual of deleterious
mutations in the viral genome. Vif counters this antiviral activity by targeting
APOBEC3G/F for proteasomal degradation in the producer cell, before it can be
packaged into outgoing virions. Cells that naturally express low levels of APOBEC3G/F
are called ‘permissive cells’, as viral replication can proceed undeterred even in the
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absence of Vif. Non-permissive cells produce APOBEG3G/F in sufficient quantities that
necessitate the action of Vif.

VprVpr is a basic 14 kDa protein produced during the late transcriptional phase of
viral gene production. It is found ubiquitously throughout the infected cell, but tends to
accumulate in the nucleus, or associate with the nuclear membrane via nuclear pore
interactions [93] [94]. Vpr is also packaged into virions, via interactions it establishes
with the p55 Gag precursor [95]. For its diminutive size, Vpr has been found to elicit an
array of distinct and often contradictory activities. There is however little consensus as to
the actual role or roles during infection. Vpr has been demonstrated to be involved in the
accuracy of reverse transcription [62, 63, 96], translocation of the viral DNA in the
context of the PIC [71], regulation of apoptosis [97, 98], transactivation of the viral LTR
[99], controlling transcription from episomal DNA [100, 101], and control of cell cycle
progression [102].
Despite this dizzying array of proposed activities, its function is dispensable for
productive infection in many immortalized cell lines, and for the infection of primary
CD4+ T lymphocytes. It does however appear to be necessary for productive infection of
macrophages [103]. The role of Vpr in control of cell cycle progression and a possible
pro-apoptotic activity is especially pertinent in some of the assays presented here. An
assay for integration frequency, which depends on selection and multiplication of cells
that are successfully transduced with a dominant selectable drug resistance marker, does
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not work if the virus expresses an active Vpr. It has been demonstrated that Vpr causes a
G2 cell-cycle arrest [102], and though there is evidence that the viral LTR is most active
during this phase of the cell cycle [104], the prevention of cell division is detrimental for
the purposes of the assay. The basis for this dilemma being the integration frequency in
this assay is determined by macroscopic observation and scoring of discrete resistant
colonies, each of which represents a single stably transduced cell that must undergo
multiple replication cycles before macroscopic perception is manageable. It cannot
however be ruled out that the purported pro-apoptotic activity of vpr might also influence
the utility of this assay.

VpuVpu is a small protein that is embedded into the plasma membrane via a singlepass transmembrane helix. It was long known that this protein enhances viral release
from the plasma membrane, but it was only recently discovered how it carries out this
function. Vpu antagonized the action of a plasma membrane protein aptly named tetherin,
which holds onto virus particles that have already pinched off from the membrane and
prevents their release from the cell surface [45]. Though the mechanism by which it
inhibits tetherin activity is not known, it is clear that in cells that express tetherin, Vpu is
required for proper viral release. It is noteworthy that CEM cells, a non-adherent human
T-cell line, is apparently preferentially infected by cell-cell transmission, as opposed to
being infected by free virions. We have observed, as others have before, that a vpu- virus
is able to significantly enhance the inherent infectivity of virus in these cultures, and that
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multinucleated membrane bound entities called syncytia, produced by cell-cell fusion, is
also enhanced by the absence of the Vpu protein [105].
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HIV-1 Integrase
Expressed initially as the C-terminal domain of the pol gene (Figure 5), IN is
packaged into budding viral particles in the context of the large Gag-Pol precursor
polyprotein. The mature 32kDa, 288-amino acid IN is produced, as is the case with all
mature gag and pol gene products, within the confines of the virion by the action of the
viral protease. After viral entry, reverse transcription of the viral RNA produces the
substrate for integration: a linear, double-stranded DNA copy of the viral genome. The
catalytic activities of IN then orchestrate the unique replicative strategy of the retrovirus
family, the insertion of the viral cDNA copy into the genome of the host cell (Figure 6).
The ultimate result of IN catalytic activity is the covalent and irreversible insertion of the
viral genome into the host chromosomal DNA, making it indistinguishable from the
genetic information of the cell. Since efficient viral transcription only occurs from the
proviral DNA form [106], integration is a crucial process for the propagation of the
retrovirus, and is the underlying basis for the perpetuation of the viral genetic information
throughout the lifetime of the infected cell, and to successive generations of daughter
cells after mitotic cell division.
The investigation of HIV-1 IN during infection has presented an especially
difficult challenge due in part to the multi-functionality of the protein. Apart from its
unique role in integration, IN is required for other distinct viral processes during many
stages of the viral life cycle [107], impacting the precision of proteolytic processing of
the Gag and Gag-Pol polyproteins, and particle morphogenesis in producer cells [47] as
well as the efficiency of reverse transcription in recipient target cells [108-113]. For
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clarity, a standardized nomenclature has been derived for describing IN mutant
phenotypes as either Class I or II [114]. Class I IN mutant viruses are efficiently
produced and otherwise infectious proceeding through all stages including reverse-

Figure 5. Position of IN in the HIV-1 genome. The nine ORFs of HIV-1 are depicted as
grey boxes. The vertical displacement of each box indicates the relative reading frame.
The IN region is blown up to show the domain structure, and the CTD is further blown up
to display the finer structural detail. The region of overlap is also shown. The sizes of the
reading frames are not drawn to scale.

transcription and viral DNA nuclear import but are blocked for the catalytic functions of
3’ processing and strand-transfer. Thus, Class I mutant infections result in unprocessed,
blunt-ended linear viral DNA intermediates that when transported into the nuclear
compartment are expeditiously self-ligated to produce circularized viral DNA molecules
(2-LTR circles), the accumulation of which is a signature feature of this mutant
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phenotypic class. In contrast, Class II IN mutants, a broader phenotypic designation,
manifests a range of pleiotropic effects including defective polyprotein processing, virion
maturation and egress in producer cells with the potential for concomitant effects during
the infection of target recipient cells, the most obvious of which is the perturbation of
reverse transcriptase activity.
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Figure 6. Overview of HIV-1 integration reaction. I) HIV-1 IN encounters its substrate
produced from reverse transcription, a linear double-stranded copy of the viral genome.
II) IN removes a dinucleotide from the 3’ ends of both strands, in the first step of
integration called 3’ processing. III) The processed DNA, in the context of the PIC,
encounters target DNA. IN directs the exposed –OH groups from the processed DNA
ends to nucleophilic attack of phosphodiester bonds in target DNA separated by 5bp on
opposing strands. IV) The immediate product, viral DNA linked covalently at the 3’ ends
to target DNA, with flanking sequences of unpaired DNA 5bp in length, and a 2bp 5’
unpaired overlap of viral DNA. V) Unpaired gaps are repaired by host DNA repair
enzymes. The proviral DNA is flanked by a duplicated 5bp sequence, characteristic of
HIV-1 integrase-mediated integration. (adapted from [115])
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Integrase Structural Domains:
The replication strategies of retroviruses and transposable elements entail
essentially parallel processes, both requiring the mandatory step of integrating the
element’s genome into a foreign DNA molecule. Indeed HIV-1 IN and the transposase
enzymes of DNA transposons and retroelements belong to a superfamily of
polynucleotidyltransferases, which includes Mu transposase, and the Escherichia coli (E.
coli) enzymes RuvC endonuclease and RNaseH [116-119]. Due to its insolubility and
propensity to aggregate at high concentrations, efforts to determine a high resolution
structure of the isolated HIV-1 IN protein, or complexed with its substrate DNA, have
thus far been unsuccessful. Nonetheless, the overall structural architecture of the enzyme
has been inferred from evidence derived from distinct experiments, including analyses of
the peptide products from limited proteolysis of susceptible linker sequences between
domains [120], in vitro complementation assays [121, 122], phylogenetic comparisons of
related enzymes [120], and the successful structural determination of the individual
protein domains [116, 122-129]. IN comprises three domains: the N-terminal domain
(NTD), the catalytic core domain (CCD) and the carboxyl-terminal domain (CTD). The
structures of each of the three domains have been determined in isolation, and twodomain structures compromising the NTD/CCD and CCD/CTD have been also been
solved.
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N-Terminal DomainThe NTD encompasses residues 1 through 49, and contains an invariant HHCC
motif conserved throughout retroviruses and retrotransposons. This motif is involved in
zinc metal co-ordination, establishing an in vitro-determined stoichiometry of 1 IN
molecule:1 Zn2+ ion [130, 131]. Metal binding has been demonstrated to facilitate the
correct tertiary folding of the domain, which assumes a helix-turn-helix topology
reminiscent of zinc-finger DNA-binding domains [131]. The resemblance ends here
however, for there is no evidence that the IN NTD can bind DNA, either in a specific or
non-specific fashion. Instead, it is believed that the NTD contributes to the ability of IN
to multimerize [131], which is an ability required by IN to conduct the integration
reaction. One report has also implicated the role of the NTD in specific interactions with
the viral DNA substrate, the lysine at position 14 identified as the specific residue [132].

Catalytic Core DomainThe CCD maintains the highest degree of sequence homology between distinct
retroviruses, compared to the other two domains of IN. This domain encompasses
residues 50-212, and contains a constellation of acidic residues that create a D,D-35-E
motif that is conserved throughout the integrase enzymes of all retroviruses, and with
those of retrotransposons and some bacterial transposons [133, 134]. These residues coordinate two divalent cations required for catalysis. For HIV-1 IN either Mg2+ or Mn2+
can be accommodated for in vitro assays of integration function, though it is Mg2+ that
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likely is the biologically relevant species [135]. Alteration of any of the three catalytic
residues abrogates all integration activity [120, 136, 137], and infections with mutant

Figure 7. The domain structures of HIV-1 IN. (A) The catalytic core (CCD) structure,
shown in dimeric form. The residues comprising the D,D-35-E motif are displayed. (B)
The N-terminal domain (NTD) depicted with the highly conserved HHCC motif, in
coordination with Zn2+. (C) The carboxyl-terminal domain (CTD). The unstructured tail
comprising residues 271-288 are unresolved, and thus not shown. For all structures, alpha
helices are in blue, beta sheets in green. (Adapted from [138])
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viruses bearing mutations at these residues characteristically accumulate high levels of
unintegrated episomal viral DNA in the infected cell, and are archetypal class I mutants.
The solved structure of the isolated CCD was solved as a symmetrical dimer with an
extensive and likely biologically-relevant dimer interface [127]. These dimeric contacts
were maintained in the crystal structure of the two domain CCD-CTD crystal, thus
further highlighting its relevance [124]. The overall topology of the CCD structure
assumes an RNaseH fold, and closely resembles the RNaseH domain found in the p66
subunit of reverse transcriptase. This characteristic folding pattern is maintained
throughout the family members of the polynucleotidyltransferases, including the E. coli
enzymes, RuvC resolvase and RNaseH [116]. Notably, the structure contains two flexible
loops, comprising residues 138-149 and 186-194. The first loop is disordered and
therefore absent from the crystal structure, and sits on the lip of a cleft which houses the
catalytic triad. The presence and importance of this flexible loop to the integration
reaction lends some insight into the dynamic structural flux required of the enzyme
during the integration reaction.

Carboxyl Terminal DomainThe CTD encompasses residues 212-288, and is connected to the CCD via an
extended α-helical coil (residues 195 to 220). Even amongst retroviruses, the CTD
exhibits minimal homology, and contains a single invariant residue, W235, common only
amongst retroviral integrases. Though relatively well-conserved, the identity of the
residue at the 235 position in HIV-1 IN is not critical, since the virus can accommodate
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certain amino acids substitutions at this position [107]. The structure of the domain was
solved by nuclear magnetic resonance (NMR) as a dimer; with the isolated monomeric
unit assuming the topology of a five-stranded β-barrel that bears striking resemblance to
an Src-homology 3-like fold (SH3) [125, 126]. Residues 220-270, which coincidentally
are the outer margins of a non-specific DNA binding activity that is inherent to the
domain, describe the boundaries of this structural element [139]. Since HIV-1 integration
sites display little if any consensus sequence, it was once thought that the non-specific
DNA binding activity of the CTD served as an anchor that would hold the IN-DNA
complex to a random site on the chromosome. This theory has however lost merit with
the discovery of IN interaction with a cellular protein, the lens-epithelium-derived growth
factor (LEDGF), which is believed to act as a molecular tether between IN and
chromosomal DNA [140, 141]. Instead, it is currently believed that the CTD non-specific
DNA binding serves to stabilize the viral DNA substrate in such a way that it forms the
appropriate contact with residues in the CCD for catalysis. Other functions ascribed to the
CTD include the roles in promoting IN multimerization [142], for coordinating the
binding of both host- and virion-derived proteins [3, 110, 143-148], and a possible role in
PIC nuclear import [72]. It was recently demonstrated that IN and RT interact, bridged
via IN CTD contacts [110, 149], and that IN enhances the efficiency of reverse
transcription [109]. The CTD is especially implicated in the facilitation of secondary IN
functions. Highlighting this, a mutagenic substitution study of the most conserved
residues shared between HIV-1/SIVcpz isolates, showed that alteration of conserved CTD
residues gave rise to predominately Class II IN mutants [2].
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The structural data for the CTD ends at the aspartic acid residue at 270, with the
remaining 18 residues (amino acids 271-288) proving recalcitrant to conventional
structural investigation due its high level of disorder. This IN ‘tail’ is predominantly
acidic, its role(s) in IN functions currently unknown. It has recently been shown that
HIV-1 IN CTD is a potent substrate for p300-mediated histone acetyltransferase (HAT)
activity [3, 4] at three lysine residues (K264, K266, K273), a phenomenon subsequently
demonstrated to be non-essential for sustained viral replication through an immortalized
T cell line [4]. The impact of IN acetylation has however not been evaluated in primary
cells, where it might play a more pivotal role. This inquiry is hindered by the overlapping
ORFs of IN and Vif. Alteration of any residue after IN 271 simultaneously alters the
amino terminus of Vif, a domain recently noted for its role in defining interactions with
APOBEC family members [150-152]. Unlike some immortalized cell-lines, Vif function
is absolutely required in the primary cell targets of HIV-1, thus the interpretation of any
mutant phenotype derived from altering residues in the IN tail is complicated by the
potential influence on Vif function. It is intriguing that K273 is the most robustly
acetylated residue [4], and is also a residue implicated for ubiquitination that impacts IN
stability [153]; it is thus frustrating to the experimenter that K273 at the very beginning
of the IN-Vif overlap.
To investigate the contribution of the IN tail, and by consequence the posttranscriptional modifications therein, we created a series of truncation mutants that
sequentially removed the tail of IN, and concomitantly the residues targeted for
posttranslational modification. These experiments were conducted in immortalized cells
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that are Vif-permissive (do not require Vif), thus removing the complicating factor of vif
alteration. The viruses were tested in a number of assays to assess the effects of
truncation on a variety of measurable viral processes. It was found that the IN tail is
dispensable for viral replication in our in vitro systems, but we discovered a number of
truncations within a very narrow window of residues that displayed strikingly dissimilar
phenotypes, manifesting gains and losses of specific viral processes.

Functions of IN:
The Integration ReactionThe primary function of HIV-1 IN is to catalyze the integration reaction. During
infection, this reaction comprises two sequential and spatially separated biochemical
activities called 3’ processing and strand transfer. Much of the mechanistic details of the
integration reaction have been deciphered from in vitro assays that use purified
recombinant IN with DNA substrates that mimic the viral DNA ends. The 3’ processing
assay directly assesses the ability of IN to remove a terminal dinucleotide from a short
DNA substrate with sequences from the viral DNA terminus, the resulting processed
products easily resolved and distinguished from unprocessed substrate (Figure 8A).
The strand transfer reaction is a relatively inefficient process when conducted in
vitro with recombinant IN and viral DNA substrates, highlighting the possible
requirement for extraneous viral or cellular factors for this integration activity. Most
reaction conditions favor the formation of ‘half site’ integration products (Figure 8B)
derived from the insertion of only one viral end into one strand of the target DNA. ‘Full
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site’ or concerted integration entails the successful insertion of both viral DNA ends into
the target sequence, in the characteristic 5bp staggered fashion of the IN of HIV-1. These
more natural products of IN integration activity can be produced in vitro with
recombinant IN and substrate DNA alone, but the process is highly sensitive to reaction
conditions, and to the concentration of IN both during purification and in the reaction
itself [154]. The completion of the integration process requires the subsequent filling of
the single-stranded gaps at the site of integration, a process undertaken ostensibly by
cellular factors in the natural infection setting.
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Figure 8. The in vitro activities of IN. A) 3’ processing. Viral DNA substrate containing
cis-acting sequences at the extreme termini, including a highly-conserved CA
dinucleotide, are endonucleolytically cleaved by IN at the scissile phosphodiester bond
between the CA and GT dinucleotides, indicated by the arrow. B) Strand transfer. IN
directs a nucleophilic attack of a phospodiester bond on a target DNA substrate, using the
exposed –OH group on the recessed end of processed DNA substrate. Most reaction
conditions favor the half-site reaction, shown here. C) Disintegration. An IN-mediated
processed observed only in vitro, it is considered a reversal of the strand transfer reaction,
resolving the intermediate DNA form produced by strand transfer into two discrete
molecules. The CCD in isolation is capable of conducting this reaction. (Adapted from
[155])
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3’ Processing3’ processing (3’ P) is the initial step of the integration reaction, and is presumed
to occur in the cytoplasm, concomitant with the completion of the reverse transcription
program. The reaction proceeds initially with IN recognition and binding of the viral
DNA substrate, which is facilitated by cis-acting attachment sites (att) found at the
extreme termini of the DNA substrate [156]. The nucleotides encompassing the att
constitute approximately 10 nucleotides, and contain a highly-conserved CA dinucleotide
that is absolutely essential for the integration reaction (Figure 9). In vitro mutagenic
analysis of the att region demonstrates the absolute necessity of the CA nucleotide for the
integration reaction, and a less stringent requirement of the sub-terminal nucleotides
[135]. After attachment, IN proceeds to cleave the terminal –GT dinucleotide from the 3’
strand at both the U3 and U5 regions, just after the conserved –CA dinucleotide. This is
accomplished by nucleophilic attack of the phosphodiester bond by a water molecule.
The recessed 3’ strand thus produced possesses a free –OH group that is used as the
nucleophile in the subsequent strand transfer reaction.
Though high resolution images of the IN-DNA complex are non-existent, several
lines of evidence indicate that 3’ P is conducted by the action of a dimer of IN molecules
acting at each end of the viral DNA. These include observations of the efficient
processing activity of cross-linked dimers versus monomeric and tetrameric forms [157],
and the concurrent loss of processing activity in conditions in which IN tetramerization is
favored [158, 159] . HIV-1 IN displays a natural propensity to multimerize and to form
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Processing by IN

Figure 9. The 3’ processing reaction. The reverse transcription process generates the
LTRs that flank the viral cDNA. At the termini of these ends are attachment sites (att)
that facilitate IN binding and processing. The CA dinucleotide, shown underlined, is a
highly conserved sequence found in retroviruses, and is essential for integration activity.
HIV-1 IN removes the –GT dinucleotide from both end of the viral DNA, activating them
for the subsequent strand transfer reaction.
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aggregates; in solution a dynamic equilibrium of monomers, dimers, tetramers, and other
high-order complexes of IN is established [142, 160]. The importance of multimerization
for integration activity is reflected in the lack of catalytic activity of monomeric IN [157],
and the abrogation of integration activity when residues known to affect IN
multimerization are mutated [131, 161]. The current model for the IN-DNA complex
during 3’ P is shown in Figure 10.

CTD

Monomer 1
Monomer 2
CCD

Viral end

Figure 10. IN dimer model for 3’ processing. This model of IN action for processing
and integration activity is based on observations from complementation studies,
crosslinking analyses, and structural data. The CTD of monomer 1 in the background
associates with subterminal sequences in the viral LTR, orienting it such that the viral
end makes contact with, and is processed by the catalytic core of monomer 2 in the
foreground. Shown in maroon is Glu 246, a CTD residue found to crosslink to viral
DNA. (Adapted from [132]).
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This theoretical model closely resembles the resolved two-domain crystal structure of the
CCD and CTD, consisting of two IN molecules associated exclusively via CCD
interactions, with the CTDs of the two subunits splayed apart by 55 angstroms, forming a
Y-shaped dimer [124]. The proposed orientation of the viral DNA substrate with the IN
dimer is such that the CTD of one monomer stabilizes the DNA so that the DNA end lies
in the catalytic site of the opposed dimer. This model satisfies certain observations of IN
biology. For example, it is well-established that two unique mutant IN monomers can
very efficiently complement each for catalysis if the mutations lie in distinct domains
[162]. Additional support for the IN-DNA arrangement during processing is derived from
the results of several crosslinking studies, demonstrating the proximity of catalytic core
residues to nucleotides at the extreme terminus of the viral DNA, while subterminal
nucleotides interact specifically with residues in the CTD [163-166]. During or after
processing of the viral ends, it is believed that IN undergoes a conformational change that
engages the complex for the subsequent strand transfer reaction [132, 163, 166].

Strand transferThe strand transfer reaction is contingent on the previous IN activity of viral DNA
end processing. The removal of the dinucleotides generates reactive –OH groups at the 3’
ends of the viral DNA, which then IN directs in nucleophilic attack of phosphodiester
bonds in the target DNA. The cleavages occur along one face of the target DNA
molecule, in the characteristic 5 bp staggered cut of HIV-1 IN. The cleavage of target
DNA and the ligation of the activated viral DNA ends occur in concert, the resulting
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product consisting of viral DNA attached covalently to host DNA at both 3’ ends. The
staggered cutting of target DNA results in a gap of single-stranded DNA 5bp in length at
both ends of the viral DNA. The 2bp overhang of viral DNA created during 3’ processing
remains unhybridized. Host DNA repair enzymes then repair the gaps, completing the
formation of the provirus. The repair of the single-stranded regions flanking the
integration site results in the duplication of a 5bp sequence that is characteristic of HIV-1
IN integration sites. (Figure 11).
Current theories posit that the strand transfer reaction is conducted by at least a
tetrameric assemblage of IN subunits, created by association of the two IN dimers that
had functioned at either DNA end during the previous 3’ processing reaction. Evidence
for this stems from in vitro work demonstrating the IN tetrameric form is responsible for
concerted integration reactions, whereas dimers can only facilitate the half-site reaction
[157]. Furthermore, it was found that LEDGF binds specifically to tetrameric IN, and
enhances concerted integration efficiency [167, 168]. A model for the assembly of IN
with substrate and target DNA is shown in Figure 12.

DisintegrationObserved exclusively in vitro, this biochemical activity of IN is essentially the
reversal of the strand transfer reaction. A branched DNA substrate, such as shown in
Figure 8, resembling the immediate product of strand transfer, is resolved by IN into two
discrete molecules. The CCD in isolation is capable of mediating this reaction [169],
underscoring the fact that the CCD houses the primary catalytic activity of IN. The
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Processed
Viral DNA

Target DNA

Integrase

Intermediate

DNA Repair

Figure 11. The strand transfer reaction. The substrate for the strand transfer reaction is
the product of the 3’ P reaction that immediately precedes it. The exposed –OH groups on
the processed viral DNA ends are used in a nucleophilic attack of phosphodiester bonds
in the target DNA, resulting in the covalent linkage of the recessed viral DNA end with
target DNA. The 5 bp staggered cut ultimately results in the duplication of this original
target DNA sequence at either end of the provirus.
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Figure 12. IN tetramer model for strand transfer. An IN two-domain tetramer model,
assembled using constraints from crosslinking and structural data, is depicted here with
associated DNAs. The two viral LTRs are colored in pink, and target DNA colored in
gray. The light and dark blue monomers represent one dimeric unit attached to one viral
DNA end, which associates with the yellow/orange dimer with its associated DNA.
(Adapted from [163])
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biological relevance of this activity is uncertain, and may simply be an artifact of the in
vitro system in which it is studied.

Secondary Integrase functions:
In contrast to the primary integration activities, far less is known of the secondary
functions of IN. It was long observed that gross deletions of IN negatively impact the
yield of virus particles from transfected cells. Other IN mutants, which appear otherwise
normal, were found to be blocked at a stage after viral release, but prior to integration.
The Class I/Class II scheme formulated for convenient categorization of IN mutant
phenotypes is little more than a broadly descriptive designation, especially so for Class II
mutants that display extensive pleiotropic effects on viral dynamics. Advantageously,
new mutants can readily be classified using this scheme, by measuring the levels of late
RT cDNA product in newly infected cells; most Class II mutants, despite the nature of
the block, are significantly less efficient at producing viral cDNA compared to Class I or
WT viruses. The only exceptions are mutants that may be blocked for nuclear import, but
not for integration itself.
Further investigation into the phenomenon of the IN-mediated effect on viral
release revealed that the disruption is based on aberrant processing of the viral
polyprotein precursors within the producer cell. Whereas processing should occur during
or after virion egress from the plasma membrane, it was apparent that deletion and some
point IN mutant viruses were processing the viral polyproteins intracellularly [47]. The
timing of protease activation after completion of assembly is crucial for the proper
packaging of viral components into the virion. Insufficient packaging of the Pol products
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into outgoing virions can also have downstream consequences for virion morphology,
reverse transcription and integration. Prematurely active PR can also have a direct
detrimental impact on assembly, since the process itself is dependent upon the
contributed activities of several domains of the intact Gag precursor. The precise
mechanisms that avert the premature activation of the viral protease within the cytoplasm
are currently unknown. Dimerization of Gag-Pol precursors is thought to be the ratelimiting step; once it occurs, the embedded viral protease self-catalyzes its own excision
by an intramolecular mechanism, and then proceeds to cleave adjacent polyproteins in an
ordered fashion [49]. The cytoplasmic ratio of 20-Gag to 1-Gag-Pol precursors in the
producer cell is likely a natural deterrent to Gag-Pol dimerization. Indeed, artificially
overexpressing Gag-Pol leads to premature PR activation in the cytoplasmic
compartment [36, 170]. Furthermore, when added to virus producing cells, the nonnucleoside RT inhibitor (NNRTI) efarivenz, which enhances the dimerization of the
subunits of the RT enzyme, triggers the premature activation of the viral protease [171]..
Speculatively, IN in the context of the Gag-Pol precursor must exert some influence over
the dimerization potential of Gag-Pol, perhaps by preventing a productive association that
would inexorably lead to PR activation.
Significant headway has been made in recent years to unravel the role that IN
plays in the reverse transcription process. The complicating factor has always been that
many Class II IN mutants can be defective at steps prior to the early life cycle events
which encompass reverse transcription. The development of an elegant method of
targeting RT and IN in trans to virus particles independently of Gag-Pol [172], has

- 55 -

effectively created a system in which viral replication dynamics can be studied in the
absence of IN influence on late life cycle events, and has thus opened the way for
investigating the specific impact of IN on reverse transcription. Using this technique, it
was clearly shown that mature IN is required for the production of viral DNA in infected
cells, via specific interactions with components of the reverse transcription complex [108,
109]. Subsequent studies revealed a physical association between RT and IN, which is
mediated by the IN CTD [110, 149]. However, the components and composition of the
PIC are unknown, and it is also feasible that IN could play less direct role in the reverse
transcription process, perhaps by recruiting other factors that interact with RT, or by
contributing a scaffolding function to foster an appropriate environment in which reverse
transcription can proceed.
IN has also been demonstrated to selectively recruit cellular proteins into virions
[173, 174]. One of these, the host DNA repair enzyme uracil DNA glycosylase 2 (UNG2)
has been shown in other studies to be incorporated by Vpr [96]. The enzymatic activity of
UNG2 removes uracil residues from G:U mismatches in double-stranded DNA, and its
recruitment to virions correlates with an enhancement of the fidelity of reverse
transcriptase [96]. This activity appears to be particularly pertinent for infection of
macrophages [175], which contain inherently low cytoplasmic dNTP levels, and high
uracil levels [176]. Another cellular protein that was found to be recruited by IN into
virions is INI1/hSNF5, a component of the chromatin remodeling SNF-SWI complex
[177]. Though it is packaged into virions, this protein’s effect on viral replication is at the
stage of viral assembly, impacting the efficiency of viral release [174]. Given the timing
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of this effect, it is apparent that INI1/hSNF5 interacts with IN in the context of Gag-Pol,
and influences events in the late stage of the viral replication program. A follow-up to
this study revealed that both INI1/hSNF5 and IN interact with SAP18, a component of
the Sin3a-HDAC1 complex, and that components of this complex are incorporated into
virions [178]. In keeping with this recruitment, HIV-1 virion preparations were
subsequently demonstrated to possess a significant level of deacetylase activity, which if
removed by overexpression and incorporation of a transdominant negative mutant of
HDAC1 negatively impacted the early reverse transcription stage. This observation is
especially intriguing, given that IN is modified by acetylation, and is involved in the
efficiency of reverse transcription.
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CHAPTER 2- MATERIALS AND METHODS

Construction of integrase mutants. The HXB2-related virus, R7/3(X/S) [4, 179], was
used as the reference, wild type virus for the studies presented. Its cognate proviral
molecular clone, plasmid pR7/3(X/S) (Figure 1), contains an XbaI restriction site at the
5’ end of the integrase coding region and a SacII restriction site near its 3’ end, the sites
silent with respect to the overlapping viral coding frames and allowing for a cloning
strategy that provides unbiased comparisons to be made against an otherwise isogenic
background. Thus, using overlap PCR mutagenesis [pR7/3(X/S) template; outside
oligonucleotide primers specifying XbaI and SacII sites], a series of translational
nonsense mutations (amber) were introduced at sequential codon positions to create a
nested set of single amino acid deletions originating from the IN C-terminus; all mutant
proviral clones verified by DNA sequence analysis of the across the entire XbaI/SacII
recombinant segment. Wild type and mutant XbaI/SacII inserts were also reconstructed
into pR7/3(X/S)Bsd [4, 179], an env- proviral derivative in which the amino terminus of
nef is substituted with bsd, a gene conferring resistance to the microbial antibiotic,
blasticidin S. Single-step infectious, VSV-G pseudotyped viral stocks were prepared by
co-transfection of the pR7/3(X/S)Bsd variants with pCI-VSV-G, a vesicular stomatitis
virus glycoprotein (VSV-G) expression vector.

Tissue culture and viral stock preparation. HEK293T, GHOST(3)X4/R5[180] and
HeLaP4R5 [181] cells were cultured in Dulbecco modified Eagle medium (DMEM)
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supplemented with 10% fetal calf serum (FCS) and 100 U/ml penicillin/100 μg/ml
streptomycin (P/S); CEM cells were cultured in RPMI 1640 supplemented with 10% FCS
and P/S. Viral stocks were generated in one of two ways. For multicycle, replicationcompetent (env+) virus, stocks were made by mixing 2 µg of proviral plasmid DNA with
12 μg polyethylenimine (PEI) and adding the mixture to a sub-confluent monolayer of
HEK293T cells cultured in 6-well plate format. Single-step viruses were made by mixing
1.5 μg viral plasmid DNA and 0.5 μg pCI-VSV-G expression vector with 12 μg PEI and
adding to HEK293T cells. For both methods, media was changed the following day and
the viral stocks harvested 48 hours post-infection (hpi) by filtration of cell-free media
through a 0.45 µm nylon filter. Viral titer was determined using data provided by p24
ELISA (PerkinElmer Life and Analytical Sciences).

Western blot analyses. Intracellular protein Transfected HEK293Tcells were disrupted
by lysis in RIPA buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 1% deoxycholate, 1%
Triton X-100, 0.1% sodium dodecyl sulfate [SDS]) supplemented with “cOmplete”
protease inhibitor cocktail (Roche) and the lysates cleared by centrifugation at 20,817 x g
for 15 min at 4˚C.
Virion protein Viral stocks, generated by proviral DNA transfection of HEK293T cells,
were normalized for p24 content (250 ng) and pelleted through a 25% sucrose cushion at
20,817 x g for 3 hours at 4˚C and the pelleted virions lysed in supplemented RIPA buffer.
Intracellular and virion protein samples were normalized for protein content [182] and 25
μg (intracellular) or 15 μg (virion) loaded onto 4-12% polyacrylamide NuPage Bis-Tris
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gels (Novex) and using reducing conditions, resolved by electrophoresis in MOPS buffer.
Proteins were blotted onto polyvinylidene difluoride (PVDF) membranes, which were
subsequently blocked, washed and incubated with monoclonal antibodies directed against
the amino terminus of IN (6G5) [183], capsid (CA) (183-H12-5C) [184] or RT (11B7 and
33D5) [185]. Blots were then incubated with rabbit anti-mouse mAb-HRP, and detected
using the Immobilon Chemiluminescent AP Substrate Detection Kit (Millipore).

Qualitative Assay for Viral Replication Competency. Detection of syncytia formation
in the highly fusogenic CEM cell line after infection is indicative of successful proviral
DNA integration and efficient env gene expression—the rate and extent of syncytia
recruitment and expansion over time, a qualitative measure of viral replicationcompetency or fitness over several cycles of growth. Wild type or mutant virus stocks
were normalized for equal p24 content and used to infect CEM cells (103) with a viral
inoculum of 5 ng p24 antigen in 200 μl of medium in 96-well round bottom plate format
or mock infected with medium alone. All infections were performed in duplicate. The
cells were microscopically monitored daily for syncytia formation over the span of a 1012 day observational period. Seven days post-infection (7 dpi) the cultures were split 1:40
and again examined daily for an additional 7 days.

Genetic Integration Assay (bsd Transduction). HeLaP4R5 cells seeded to
approximately 30% (24-well plate format) and inoculated overnight with a normalized
amount of virus (5 ng p24). Twenty-four hours later the cells were washed twice with
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PBS and fed with fresh DMEM for an additional 24 hour growth period, after which the
cells were split into selection media containing 5 μg/ml blasticidin HCl. Selection was
imposed for an additional 14 days and then resistant colonies were fixed, stained and
scored macroscopically for the number of resistant colonies.

Quantitative PCR Analyses. Late RT and 2-LTR Viral stocks were pretreated with
Turbo DNase (Ambion) at a concentration of 40 U/ml at 37˚C for one hour before
infecting confluent GHOST(3)X4/R5 cells with 50 ng p24 per well in 24-well plate
format in the presence of 8 μg/ml polybrene. Infections were spinoculated for 2 hours at
15˚C at 2400 rpm 1,160 x g before transferring the cultures to a 37˚C humidified
incubator for 8 hours. At this time, total cellular DNA was prepared for late RT product
determinations, or 16 hours later (24 hpi) for the quantification of 2-LTR circular DNA
accumulation. The QiaAmp DNA Blood Mini Kit (QIAGEN) was used for all isolations,
the extent of late RT and 2-LTR circles formation determined by molecular beaconmediated quantitative PCR analysis using primers specific for each type of amplification.
Late RT: Forward primer (5’-AGATCCCTCAGACCCTTTTAGTCAGTGTGG-3’) with
reverse

primer

(5’-GCCGCCCCTCGCCTCTTG-3’)

and

FAM\ccgacccTCTCGACGCAGGACTCGGCTTgggtcgg\3Dab\-3’);

beacon
2-LTR

(5’-\56Circles:

Forward (5’-CTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTA-3’) with reverse
primer (5’-TGACCCCTGGCCCTGGTGTGTAG-3’) and beacon (5’-\56-FAM\ccgcacC
TACCACACACAAGGCTACTTCgtgcgg\3Dab\-3’).
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Alu PCR Integration Assay Infections and DNA extractions were performed identically
as for 2-LTR quantitative PCR analyses. Using a modification of the twin PCR
amplification protocol designed by Chun et al. [186], extracts were normalized for DNA
content and then subjected to two rounds of PCR, the first of which uses a forward primer
specific to the Alu repetitive element (5′-TCCCAGCTACTCGGGAGGCTGAGG-3′)
and a reverse primer (5′-AGGCAAGCTTTATTGAGGCTTAAGC-3′) localized to the
U3 region of the HIV-1 LTR. The reaction conditions for the first round PCR were as
follows: 94˚C x 3 min and then 22 cycles of 30 sec x 94˚C, 30 sec x 66˚C with a 5 min
extension reaction at 72˚C followed by a final 10 minute extension at 72C. One/one
hundred and twentieth (1/120th) of the first round reaction was then subjected to a second
round of PCR, here modified for beacon-mediated quantitative PCR analysis using a
nested primers (5’-GAAGGGCTAATTCACTCCCA-3’, 5’-CTTGAAGTACTCCGGAT
GCAG)

in

the

LTR

in

conjunction

with

a

molecular

beacon

(5’-/56-

FAM/ccgcacCTACCACACACAAGGCTACTTCgtgcgg/3DAB/-3’). The second round
PCR reaction used the following reaction conditions: 10 min x 94˚C and then 50 cycles
of 30 sec x 94˚C, 33 sec x 63˚C and 30 sec x 72˚C. Integration standards for qPCR
analysis were produced by infecting HeLa P4R5 or GHOST(3)X4/R5 cells at a low
multiplicity of infection (moi) of BSD (WT IN) virus, subjecting cells to a week-long
selection at low density, and extracting total DNA 8 dpi. DNA from these cells was
subjected to the first round PCR, and diluted 40x. A dilution series of this 40x diluted
first round PCR was used as the standard by which the tested viruses were compared for
quantification.
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Ligation-Mediated [187], Quantitative PCR (LMqPCR) Assay for 3´ Processing
Infections and DNA extractions (8 hpi) were carried out under identical conditions as that
used for late RT PCR analyses. Here, extracts were normalized for DNA content and then
incubated for 12-16 hours at 16˚C in a 15 μl reaction mixture containing 500-750 ng total
cellular DNA and an equimolar amount of two oligonucleotide primers (each 2 μM final):
LMqPCR-short

(5΄-OH-GTACTCATGTA-OH-3’),

LMqPCR-long

(5΄-OH-

GTCTAGAGCTCAGCTGTACATGAGT-OH-3’). LMqPCR-short (11 base-pairs) is
complementary to LMqPCR-long over 9 contiguous nucleotides (LMqPCR-short
nucleotides 3-11) such that when annealed, the double-stranded oligonucleotide produces
a two base-pair 5’ overhang (nucleotides G1 and T2), the exact compliment to the 2 basepairs left unpaired after integrase-mediated 3’ processing at each end of proviral DNA
(5’-AC-3’), the rest of LMqPCR-long remaining single-stranded and used to anchor a
subsequent quantitative PCR assay. Upon ligation, the single phosphate group at each of
the 5’ ends of linear proviral DNA is covalently linked to the 3’ end of the LMqPCR-long
primer DNA. Ligation reactions were performed with 10 U of E. coli ligase (Takara) in
1x E. coli DNA ligase buffer (New England Biolabs). Since both LMqPCR-short and
LMqPCR-long are unphosphorylated, the oligonucleotide pair is relatively inert with
respect to promiscuous ligation events, incapable of their individual oligomerization or
the formation of multiple concatemers upon the ends of the proviral DNA. After ligation,
the reaction was incubated at 65˚C x 20 min to inactivate the enzymatic activity of the
ligase and then one-third of the ligation reaction (5 μl) was supplemented with the
addition of the LMqPCR-long primer and subjected to qPCR analysis, the ligated DNA

- 63 -

products quantified using beacon-mediated qPCR analysis using LMPCR-long and an
HIV-1 LTR primer/beacon oligonucleotide set specific for monitoring the efficiency of 3’
processing events at either the 5’ or 3’ LTR. 5’ LTR primer/beacon pair: (5’CTTGCTCAACTGGTACTAGCTTGTAG-3’) used in conjunction with (5’-/56FAM/ccgcacCTACCACACACAAGGCTACTTCgtgcg

g/3DAB/-3’);

3’

LTR

primer/beacon pair: (5’-GGGAGCTCTCTGGCTAACTAGG-3’) used with (5’-/56FAM/ ccgaaccaGTAGTGTGTGCCCGTCTGTTGTGtggttcgg/3DAB/-3’). Controls for
all quantitative PCR reactions above include IN D116A virus (no IN enzymatic activity)
and an RT mutant virus (D185A/D186A) [4] with no polymerization activity, the latter a
control for bacterial contaminant DNA left over from the preparation of viral stocks. An
additional ligation specificity control was included for LMqPCR analyses. Here, an
oligonucleotide (LMqPCR-shortTG, 5΄-OH-TGACTCATGTA-OH-3’) complementary to
LMqPCR-long and identical to LMqPCR-short except for the first two nucleotides where
G1 and T2 have been reversed (T1 and G2). As a result of this modification, LMqPCRshortTG is mismatched with the unpaired 5’-AC-3’ dinucleotide left after integrasemediated 3’ processing, the LMqPCR-long/ LMqPCR-shortTG oligonucleotide pair
unable to be efficiently ligated during the first step of the procedure.

Southern blotting. Viral stocks were pretreated with Turbo DNase (Ambion) at a
concentration of 40 U/ml at 37˚C for one hour before infecting confluent
GHOST(3)X4/R5 cells with 500 ng p24 per well in 6-well plate format in the presence of
8 μg/ml polybrene. Infections were spinoculated for 1 hour at 25˚C at 2400 rpm (1,160 x
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g) before transferring the cultures to a 37˚C humidified incubator for 26 hours. At this
point, total cellular DNA was extracted using the QiaAmp DNA Blood Mini Kit
(QIAGEN). 5 μg of DNA were digested with 20U of BamH1 (NEB) and 9U of Msc1
(NEB) overnight at 37°C, heat-killed and electrophoresed on a 0.6% agarose gel, and
then transferred to nitrocellulose membrane by upward capillary action. The transferred
DNA was crosslinked to the membrane using a Strategene UV-crosslinker, and the
membrane was incubated for 10 minutes in a prehybridization step with SIGMA Perfect
Hyb (Catalogue# H7033) containing 100 μg/mL denatured salmon sperm DNA at 68°C
in a rotation hybridization chamber. The probe was synthesized by PCR amplification of
a region of the R7/3 (X/S) plasmid flanking the upstream Msc1 restriction site (Primers:
5’-CTAGAAGAAATGATGACAGCATG-3’and 5’-CTGTTAGTGCTTTGGTTCCTCT
AAG-3’). The PCR product was gel purified and radioactively-labeled with α-P32-ATP
(Perkin Elmer Easytides nucleotides 100μCi, Cat# BLU512H100UC) by random priming
using the Ambion Decaprime II kit (Cat#1455). Unincorporated nucleotides were
removed by passing the reaction over a NucAway Spin column (Cat# AM10070). The
probe was denatured for 10 minutes at 100°C, incubated on ice for two minutes, and
added to the prehybridization solution with the membrane, which was incubated with
rotation at 68°C overnight. The membrane was initially washed in 2x SSC in 0.1% SDS
wash buffer at room temperature. Subsequent washes were carried out at 68°C with 0.5x
SSC/0.1% SDS and 0.2x SSC/0.1% SDS for 15 minutes each. The blot was then exposed
to a phosphor screen, which was developed on a Storm Imager. Image analysis was
conducted with the supplied software.
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Microscopy and IN chromatin binding studies. 293T cells plated at 30% confluency
on poly-L-lysine-treated (0.01% solution, Sigma) coverslips were transfected with 0.5 μg
plasmid DNA encoding various eGFP-IN truncation fusion proteins. At 12 hours posttransfection, cells were washed, fixed with 4% paraformaldehyde and mounted onto
microscope slides with Vecta-Shield mounting media containing 4,6-diamino-2phenylindole (DAPI) for nuclear staining (Vector Laboratories, Burlingame, CA). An
inverted DeltaVision optical sectioning microscope (Applied Precision) was used to
collect between 70 to 80 images spaced at 0.2 µM through the slide. The images were
deconvolved using the DeltaVision deconvolution software (Applied Precision).

Primary cells culture. Primary memory CD4+ T were isolated by magnetic negative
selection from Ficoll-Paque (Catalogue# 17-1440-02) purified peripheral blood
mononuclear cells (PBMC) over an LS column as per the manufacturer’s protocol
(Miltenyi Biotech, Catalogue# 130-091-893). The purified cells were cultured in RPMI
1640 supplemented with 2% heat-inactivated human serum and 100 U/ml penicillin/100
μg/ml streptomycin (P/S). Cells were stimulated with 5 μg/ml phytohemagglutinin (PHA)
for approximately 12 hours prior to viral challenge.

RNA extraction and Reverse transcription. Transfected or infected cell lysates were
homogenized on a QIAGEN QIAshredder homogenizer, and total RNA was retrieved
from the cleared lysate using the QIAGEN RNeasy Mini kit. Any contaminating genomic
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or viral DNA was removed by on-column digestion with the RNase-Free DNase Set
(Catalogue# 79254). The RNA was reverse transcribed using the Thermo X reverse
transcription kit (Invitrogen, catalogue# 11150100) using recommended parameters as
per the manufacturer’s directions, and the cDNA was subject to amplification using a
primer upstream of the HIV-1 major splice donor (MSD), and another specific to the Vif
or Vpr spliced transcripts.

Viral evolution experiments. A replication-competent IN 269 (5x) stop virus was used
in the viral evolution experiments. This virus contains five engineered stop codons: three
in the IN reading frame, and two others in the two alternative reading frames downstream
of the 269 codon (Figure 33). Two virus backgrounds were used: Vpr-, vpu-, and vprvpu+. CEM-SS cells were infected with the viruses, and passaged every four to five days,
or when cells became confluent, for several weeks. After every three or four cell
passages, viral supernatant from the infected cultures were spun down to pellet the cells,
and the cell-free media used to commence infection of fresh cells. Cultures were
monitored for the formation of syncytia every few days. Concurrent with the observation
of an unusual rate of syncytia formation in the cell culture, total DNA was extracted from
cells, the IN region of the virus was amplified by PCR, and sent for sequence analysis of
the bulk PCR product. The presence of revertant viruses was ascertained by observing the
chromatogram traces. The PCR amplified viral gene products were subsequently cloned
back into the parental plasmid, transformed into the DH10B E. coli strain, and individual
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colonies were picked, grown up, and the viral DNA plasmid was sequenced to detect the
presence of individual viral revertant clones.

- 68 -

CHAPTER 3- RESULTS

Preliminary Findings

REPLICATION COMPETETENCY OF IN TRUNCATED VIRUSES:
Microscopic examination of syncytia formation is a convenient method to monitor
the extent of viral replication through cell culture in vitro, as both viral integration and
proviral gene expression of the viral envelope glycoprotein (gp120) are required for its
appearance. Using this assay, the panel of C-terminal integrase (Gag-Pol) truncation
mutants, shown in Figure 13, was initially tested to determine which mutants were
capable of sustained viral replication in the susceptible host human T cell line, CEM-SS.
This particular CEM strain is Vif-permissive and chosen for the initial characterization of
the deletion mutants since a portion of the integrase coding frame overlaps with the 5’end
of the vif gene (integrase codons 271-288) (Figure 5). Therefore, any possible influence
of the associated mutagenesis of the Vif protein might have among the panel of integrase
mutants was removed from consideration and irrelevant to the interpretation of the results
obtained.
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ResultsQualitatively, the rate of syncytia formation appears to be in positive correlation
with increasing length of the integrase protein, the WT virus (288 amino acids) producing
detectable syncytia within 3 days and rapidly leading to cell death of the entire culture
within 7 days (Figure 14). Intriguingly, although viral replication competency is lost after
removal of the terminal 16 amino acids of the protein (i.e., mutant IN 272), it is regained
in mutant IN 269 but lost again for all further truncations N-terminal to this position. The
same results were obtained across wide multiplicities of infection (data not shown).
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Figure 13. Panel of IN truncation mutants. (A) The HIV-1 genome is depicted at top,
the ORFs of the viral proteins depicted as discrete blocks. The IN protein, encoded
initially as the C-terminus of the Pol protein, is blown up to illustrate the domain
architecture of IN. The CTD is further magnified to reveal the structural features of the
domain: the α-helical hinge attaching the CCD to the CTD is depicted in black, the SH3
folded region (220-270) in light blue, and the unstructured tail 18 amino acid in dark
blue. (B) Amino acid sequence of the CTD. The letters are colored according to the
scheme used to depict the structural elements of the CTD in (A).
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Figure 14. Replication competency of IN truncations. A) CEM cells infected with a
low inoculum of replication competent IN truncated mutant viruses were observed daily
for the formation of syncytia. + syncytia detected, - no syncytia observed two weeks post
infection. ΔIN: a stop codon is introduced at the beginning of the IN ORF to remove the
entire IN protein. RT-: control virus containing mutations in the reverse transcriptase
protein that destroy RT catalytic activity, without affecting any viral function other than
reverse transcription. ND: No Data. B) Replication competent viruses produce syncytia in
CEM cells; cells infected with replication incompetent viruses continue to proliferate
normally without detectable virus-induced cytopathic effects.
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INTEGRATION FREQUENCY OF IN TRUNCATED VIRUSES:
It has been previously established that sustainable viral replication in culture is
contingent on an integration rate that is at a minimum 10-15% of the wild type rate. Since
alterations were being introduced into the enzyme responsible for integration, the
integrative capacity of the truncated IN viruses were assessed. The obtained results could
verify whether this previously established correlation of minimal integration rate and
replication competency could account for the behavior of the IN truncation panel in the
syncytia formation assay. The integration frequencies were measured in two distinct
assays: one genetic, and one biochemical (Figure 15). First, in the BSD assay, we
examined the ability of the viruses to stably transduce a susceptible cell line with a
dominant selectable marker for blasticidin resistance. In order to specifically gauge
integration and not viral replication dynamics, we limited infection to a single round by
pseudotyping HIV-1 env- BSD viruses with the pantropic, vesicular stomatitis viral
envelope glycoprotein (VSV-G). We included as an integration negative control the IN
D116A catalytic mutant, a well-characterized Class I mutant known to possess virtually
no integration activity, but efficiently performing all other integrase-facilitated processes.
Blasticidin resistant colonies, each one of which is tantamount to a successful integration
event, were scored, and for each virus, expressed as the percentage of the WT integration
frequency (Table 2). The second method used to measure integration frequency is an
adaptation of the Alu-PCR integration assay developed by Chun et al. Unlike the BSD
integration assay, the readout of the Alu PCR assay is not contingent on viral gene
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expression; instead, it is, by virtue of its qPCR component, a direct quantitative
assessment of the level of the integrated form of viral DNA.
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Figure 15. Assays for measurement of integration ability. (A) The BSD assay,
integration is determined by macroscopic scoring of drug resistant colonies. B) The AluPCR Assay, a first PCR round amplifies DNA regions intervening integrated provirus
DNA and Alu repeat elements. The second round uses nested primers to detect the
amplified DNA from the first round.
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ResultsThe integration rates of the IN truncation panel were measured by two distinct
methods, the results presented in Figure 16 and 17. Side-by-side comparisons reveal the
concordance of the independently-derived integration rates for each mutant virus.
Furthermore, the values derived from both assays establish a similar trend of integration
frequency across the panel of truncations. When examined in light of the observed
syncytia-formation capabilities, the integration frequency trend correlates precisely both
with an ability to replicate (≥10-15% of WT rate), and the rate with which syncytia
overtook the individually infected cultures.
The discrepancy in the integration frequency of the IN D116A mutant in the two
assays is due to an inherent drawback of the Alu PCR assay. IN D116A is a paradigmatic
Class I mutant, producing copious levels of cDNA upon infection. Lacking integration
catalytic activity, however, the DNA persists, at least in the short time frame of the Alu
PCR assay (24 hours post infection) as linear and circularized DNA species. The first
preamplifying PCR reaction of the assay serves to enrich Alu element-LTR intervening
sequences, for detection in the second qPCR round by HIV-1 LTR nested primers.
Though not specifically amplified in the first round, 1- and 2-LTR circular species yet
present in the cellular DNA extract will nonetheless be carried over into the second round
where they can function as a template for the HIV-1 specific nested primer pair. In this
regard, the BSD assay is a more reliable measurement of integration, since unintegrated
forms of DNA do not support levels of gene expression required to provide drug
resistance. Furthermore, the long selection period (2 weeks) facilitates the loss of these
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unintegrated species through dilution from multiple rounds of cell division, or by
degradation.
Having established the respective integration capacity of each IN truncation
mutant, and observing a correlation between these and replication competency, the next
step was to determine why the integration rates were low in some mutants. Since
mutations within IN can specifically affect the catalytic steps of integration, or
alternatively, can induce otherwise pleiotropic effects, we initially endeavored to broadly
classify our mutants according to the Class I/Class II scheme, establishing a stepping
stone for more in-depth investigations.

Figure 16. BSD Assay on IN truncations. Results are shown graphically in Figure 17.
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Figure 17. Integration frequency of IN truncations. The results of the (A) BSD and
(B) Alu-PCR assay depicted graphically, the integration rates of the mutants expressed as
a percentage of the WT rate.
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CATEGORIZATION OF NON-REPLICATING IN TRUNCATIONS INTO CLASS
I/II PHENOTYPES:
The panel of IN truncation mutants can be segregated according their replication
competency (Figure 14). We have established the integration/transduction efficiency of
each and observed a direct correlation between the integration frequency of the respective
truncation mutant and their ability to replicate through CEM cells. In some integrase
mutants, the loss of transduction ability is rooted at the integration step itself.
Alternatively, one or more points after proviral establishment could be affected including
those steps (i.e., assembly or reverse transcription) leading up to integration in the next
infected recipient cell. As the Class I/Class II designation of IN mutants is a convenient
descriptive apparatus, we first separated the mutants into these broad phenotypic
categories based on the straightforward method of direct measurement of the efficiency
of mutant reverse transcription-mediated viral cDNA synthesis. Since integration
proceeds after the completion of reverse transcription, replication-incompetent mutants
that produce high levels of viral cDNA are likely defective specifically for one of the two
catalytic processes of integration, and are thus categorized as Class I mutants. The
alternative replication-incompetent IN mutant group, those that produce little or no viral
cDNA, are blocked for reverse transcription, and a priori are Class II mutants.
A situation can also arise in which a virus can produce significant viral cDNA, yet
is unable to effectively shuttle the PIC components across the nuclear membrane. This is
a plausible scenario, since IN has been implicated both in direct and indirect roles for PIC
nuclear import. Here it would be misleading to characterize this mutant as Class I, since
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the defect is primarily for nuclear import. Thus, to rule out a nuclear import defect as a
cause, 2-LTR circles are also quantified. As mentioned, these circular species are used as
a surrogate marker for nuclear localization of viral DNA, and its accumulation is
symptomatic of Class I mutant infections, as is observed for the prototypical Class I IN
mutant, D116A.
The IN truncation panel was assayed for the production of late RT product, which
corresponds to the product of an advanced stage of the reverse transcription process, its
presence indicative of normal RT function. Cells were infected and total DNA was
harvested at eight hours post infection (8 hpi), corresponding to a point of robust viral
DNA synthesis in WT infections, as established in our laboratory and in other reports
[188]. For the quantification of 2-LTR circles, cells were harvested at 24 hpi, the
corresponding point at which the levels of this particular viral DNA species is at its
maximum. The results are shown in Figure 18.
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Figure 18. Late RT product and 2-LTR circle formation. A) Levels of late RT
product, a measure of RT efficiency, were quantified by real-time PCR analysis at 8 hpi.
B) 2 LTR circles, surrogates for successful nuclear impart, were quantified at 24 hpi. The
IN D116A and WT viruses reveal expected results.
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ResultsGuided by the levels of late RT and 2-LTR circle formation in WT and in the
prototypic Class I catalytic mutant, IN D116A (Figure 18), the replication and integration
defective IN truncations (Figure 14, 16 and 17) can be categorized into Class I or Class II
mutants. IN mutants truncated past IN 269 (IN 260, 265-268) can be classified as class II
mutants on the basis of their inability to produce significant levels of viral cDNA. In
contrast, replication defective IN 270, 271 and 272 viruses produced approximately WT
levels of late RT product, and elevated levels of 2-LTR circles. Notably, the circular
DNA levels of these viruses did not accumulate to the significant levels produced by the
extreme catalytic-defective IN D116A mutant virus. Though these latter viruses (IN 270,
271, 272) did not display as extreme a phenotype as IN D116A, they will be classified as
class I mutants, defective primarily for integration.
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D116A RECOMBINANTS OF IN TRUNCATIONS:
The discrepancy of integration activities and propensities to produce circular
DNA forms in the IN truncations could potentially impact our assessment of the reverse
transcription efficiency of the different mutants. This is because the amplicon that is used
for late RT PCR analysis is present not only in the late RT product, but also in the linear,
circular and proviral DNA forms. A possible confounding factor is that these DNA forms
could exhibit unique PCR amplification kinetics thus creating an over-or-under
estimation of late RT levels, based on the major DNA form present. Furthermore,
integrated DNA is in a protected form, whereas some extrachromosomal DNA species
might be subject to degradation (especially linear viral DNA). Furthermore, integrated
DNA is duplicated as a component of the host chromosome during interphase S phase
replication, and thus proviral products would not be diluted in relation to increasing
cellular DNA. In contrast, extrachromosal DNA levels are predicted to be static only for
short periods of time, subsequently diluted in relation to cellular DNA with ensuing
chromosomal replication and cellular division.
The 8 hour time point for harvesting DNA was chosen so as to lessen from
consideration the impact of these alternative DNA fates from the analyses, since
circularization and integration peak at later time points. To remove the potential of these
complications, we recombined each of the IN truncations with the D116A-inactivating
catalytic mutation. Without the possibility of integration, each virus should produce viral
cDNA in a quantity predetermined by its inherent efficiency of reverse transcription,
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producing extrachromosomal DNAs subject to the same cellular conditions and thus to
unbiased scrutiny. The results are presented in Figure 19.

ResultsIn this experiment, total DNA was harvested at 20 hpi, and analyzed both for
levels of late RT product, and 2-LTR circles. The primers used in the late RT PCR will
amplify a DNA product synthesized at an advanced stage of reverse transcription, and
which is present in all subsequent DNA species, including linear full-length DNA, 1- and
2- LTR circles as well as integrated DNA. Since these viruses are recombined with
D116A, integrated forms are removed from consideration, and thus the late RT value will
give a measure of total extra-chromosomal DNA levels. The respective profiles of the
late RT product formation in Figure 19A corroborate the initial observation that efficient
reverse transcription begins with the addition of the natural arginine residue at position
269 (Figure 18A). Full length IN with the D116A mutation (labeled 288 in Figure 19)
produces expectedly high quantity of circles. Contrastingly, catalytically-active virus
(WT) produces predictably low levels of 2-LTR circles. It is interesting to note two
things about these results. Firstly, the levels of 2-LTR circles for the D116A derivatives
closely follow the levels of late RT product, indicating that at this time point 2-LTR
circles represent a significant fraction of the total DNA in the cell. Since all the viruses
are catalytically inactive, blunt-ended DNA products should accumulate to produce 2LTR circles. The second observation is that the viruses appear to cluster into two groups,
based on the levels of 2-LTR circles produced. IN 275, 276, 277 and 282 appear to be
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more proficient at making circles, nearly on par with the full-length D116A virus. On the
other hand, the shorter molecules, IN 269, 270, 271, 272, 273 and 274, contain fewer
circles. This pattern is maintained when the 2-LTR circle levels are adjusted to the late
RT values, which gives the relative proportion of 2-LTR circles to total DNA. Though
the difference is not striking, it may indicate a slight delay in the ability of IN 269
through 274 to get into the nuclear compartment, perhaps remaining for a longer period
of time as linear DNA.
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Figure 19. Late RT product and 2-LTR circle formation of recombinant D116A IN
truncation mutants. IN truncations were recombined into the IN D116A background to
abrogate integration activity, and tested for late RT product formation (A), and 2-LTR
circle production (B). The quantity of 2-LTR circles relative to late RT product is
displayed in (C).
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SummaryThe panel of IN mutant viruses was tested for the ability to efficiently conduct
reverse transcription in infected target cells, as a means of delineating Class I IN mutants
from Class II mutants. We discovered that robust reverse transcription activity began in
IN truncated to residue R269, but was lost for all other truncations N-terminal to this
position. Reverse transcription activity was not lost the replication incompetent IN 270,
271 and 272, but rather was as efficient as the replication competent viruses close in
length (IN 269 and 273). Thus the replication defective truncations IN 260, 265, 266, 267
and 268 can be classified as Class II mutants that are defective for viral processes other
than integration, and IN 270, 271 and 272 can be designated as Class I mutants, blocked
specifically at integration (Figure 20)
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Figure 20. IN truncations fall into two phenotypic groups. A summary of the
phenotypic classifications of the IN truncations tested. Green dots indicate replication
competent viruses. Red dots denote replication defective viruses. The defective viruses
fall into two IN phenotypic groups: IN 260-268 are Class II mutants with pleiotropic
effects on viral dynamics, and IN 270-272 are Class I mutants, defective specifically for
the integration reaction.
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Class I Truncated IN Mutants

FATE OF VIRAL DNA IN CLASS I MUTANTS:
The observed levels of 2-LTR circle production for the IN truncation panel
(Figure 18B) raises the question of the fate of viral DNA in the class I mutants IN 270,
271 and 272: if integration is so severely attenuated, and the quantity of 2-LTR circles
does not approach the level observed in IN D116A, then what is the fate of the reversetranscribed DNA that is being produced at normal levels? Reverse-transcribed viral
cDNA can either be integrated, become circularized into extra-chromosomal 1- or 2-LTR
species, or persist in its original linear form. Unfortunately, only two (integrated and 2LTR circles) of the DNA forms can be conveniently gauged by quantitative PCR
methods. Integration, as we have shown, can be quantified by genetic means, and by an
Alu-PCR real-time-based assay. 2-LTR circles are amenable to specific detection in realtime PCR-based assays by amplifying across the unique amplicon created by LTR-LTR
juxtaposition. There is, however, no primer pair combination that can be designed for 1LTR circles or linear DNA species that would not simultaneously detect all four forms of
viral DNA.
To investigate the fate of the viral cDNA as it passes from its synthesis into one of
its four possible forms produced during infection, we applied a technique described by
Zennou et al. [74] (Figure 21A). Here, DNA extracted from infected cells is first digested
by specific restriction endonucleases that cleave the viral DNA in a predicted fashion,
creating uniquely-sized products derived from the various viral DNA forms. These can
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then be resolved by gel electrophoresis, and detected by Southern blot analysis using a
labeled oligonucleotide probe that at one end is complementary to a sequence common in
all four uniquely-sized fragments. The probe is designed such that it overlaps the
cleavage site of one of the endonucleases, and so it can simultaneously detect the level of
a second specific viral DNA fragment that is liberated from all the viral DNA forms. This
fragment thus represents the total viral DNA presence in the sample. The results are
displayed in Figure 21B.
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A.

B.

Figure 21. Analysis of the fate of viral DNA in IN truncations. (A) A schematic of the
method used to probe the levels of the various forms of viral DNA produced after
infection (Adapted from [74]). (B) The levels of viral DNA forms can be observed from
the Southern blot analysis of the restriction digested viral DNA present in the IN
truncation infections.
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ResultsIn terms of the relative abundance of each unintegrated DNA product, a trend can
be observed proceeding from left to right. Clearly, in the first set of truncations (IN 269
through IN 274), the predominant unintegrated DNA species is the 1-LTR circle. This is
especially apparent in IN 269, 270, 271, 272 and 273 and perhaps 274. 2-LTR and linear
forms are present in approximately equivalent abundance in these mutants. This pattern
changes in mutants IN 275 to IN 277, the abundance of each unintegrated species appear
to be approximately equivalent in these viruses. IN 282 and WT display roughly equal
levels of linear and 1-LTR DNA but diminished amounts of 2-LTR circles. As expected,
the dominant form of unintegrated DNA in the D116A mutant is the 2-LTR circle, with
the 1-LTR and linear DNA forms present at a similar level.
These results appear to answer the question of the fate of viral DNA in the Class I
IN mutants (IN 270, 271, 272). These Class I mutants do not produce 2-LTR circles with
the same efficiency as the typical Class I IN D116A mutant, but instead preferentially
produce 1-LTR circles. Since blunt-end viral DNA can be prodigiously ligated end-toend to produce 2-LTR circles, it is conceivable that these Class I IN truncations are able
to 3’ process at least one of the viral DNA ends, thus making it a less favorable precursor
of the 2-LTR circle, and placing it instead on a preferred path to 1-LTR circle formation.
The precise mechanisms by which 1-LTR circles are unknown, and thus it can only be
inferred that 3’ processed viral DNA is a preferential substrate for 1-LTR circle
formation. This conjecture may have some validity, in light of the fact that IN 270, 271
and 272 clearly retain some vestigial integration activity, whereas D116A has none

- 95 -

(Figure 17). The results of the D116A IN truncations also seemed to indicate that IN 269274 may be delayed in nuclear import of the viral DNA, which could permit more time to
process the DNA ends prior to nuclear entry. To follow up on these questions, and others
concerning the efficiency of the integration reaction, we were determined to assess the
efficiency by which the IN truncation mutants 3’ process the viral DNA ends. We thus
developed a method of measuring the relative in vivo levels of processed viral DNA as
described in the following section.
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3’ PROCESSING EFFICIENCY OF IN TRUNCATION MUTANTS:
Well-established in vitro protocols for detecting the 3’ processing activity of IN
mutants exist, but the artificial conditions of these assays, using isolated IN with viral
DNA mimics, often result in discrepant results between in vitro and in vivo observations.
To assay the efficiency of this first step of the integration reaction set directly during
infection, we developed a ligation-mediated PCR assay that specifically detects the
relative quantities of each of the 3’ processed viral DNA ends in infected cells. The
protocol is outlined in Figure 22 and in the Methods section, but will be described here
briefly: normalized, total DNA extract from cells infected for 8 hours (approaching the
peak of late RT product synthesis) is incubated at 16°C in a ligation reaction containing a
double-stranded donor DNA substrate, ligase buffer, and E. coli ligase. The doublestranded donor DNA substrate is produced by the annealing of a short single-stranded 11
bp oligonucleotide to a significantly longer single-stranded oligonucleotide, a process
that is facilitated by the low temperature of the ligation step. The annealed
oligonucleotides produce a double-stranded donor substrate that possesses at one end a
two bp overhang that is complementary to the exposed dinucleotide on the 3’ processed
viral DNA end. E. coli ligase was selected for its lack of ligation activity for blunt-ended
DNA substrates; the enzyme can only ligate together sticky-ended substrates. This
characteristic decreases the likelihood of errant and promiscuous ligation of the sticky
double-stranded substrate DNA to blunt-ended, unprocessed viral DNA, thus enhancing
the specificity of our assay.
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Figure 22. Schematic of quantitative LMPCR 3’ processing assay. Details of the
protocol are given in Methods.
The successfully-ligated products in the ligation reaction are then used as the
template in a beacon-mediated quantitative real-time PCR step with primers
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complementary to the longer strand of the donor substrate and to an internal LTR
sequence. The directionality of the LTRs facilitates the independent investigation of the
extent of processing at either end of the viral DNA. The high annealing temperature of
the quantitative PCR step discourages annealing by any 11 bp primer carried over from
the ligation reaction, which would decrease the efficiency of the reaction.
To satisfy proof-of-principal considerations, the assay was applied in control
experiments with the WT and IN D116A virus. WT virus processes the viral DNA
expeditiously and provides a strong signal in the assay, whereas IN D116A produces
negligible levels of processed product. The extent of end-processing was assayed at both
the 5’ and 3’ LTRs in these pilot experiments, and as the results in Figure 23A and B
indicate, the predicted pattern of processing for both viruses was evoked, with IN D116A
operating at 0.5% WT efficiency at the 5’ LTR, and 2.4% efficiency at the 3’ LTR. To
ensure the specificity of the ligation reaction, another experiment was conducted in which
the sequence of the 2bp overlap of the double-stranded donor DNA substrate was
reversed, so as to destroy complementarity with the dinucleotide overlap on the processed
viral DNA. The results are shown in Figure 23C and demonstrate that the ligation
reaction requires perfect base pair complementation, and thus addresses the assay’s
specificity. The panel of IN truncations was then examined using this assay, and the
efficiency by which viral DNA is processed was determined 8 hpi (Figure 24).
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Figure 23. Quality control for LMQPCR reactions. (A) Real-time PCR analysis of the
quantity of processed 5’ LTR (U3) DNA in WT and IN D116A mutant virus. (B) The
same analysis is conducted for the 3’ LTR (U5). (C) The specificity of the assay is
reflected in the inability of a mismatched dinucleotide overhang on the donor substrate to
be ligated to processed viral DNA.
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ResultsShown in Figure 24 are the levels of processed DNA ends of the IN truncation
panel, taken at 8 hpi, and measured at the 5’ LTR terminus. Similar results were obtained
for the 3’ LTR end (data not shown). The pattern of the relative levels of processed viral
DNA for the panel of mutants recalls the respective integration frequencies for these
mutants (Figure 17). It is evident that a direct correlation can be established between the
two. These results indicate that the amount of 3’ processing detected for these mutants is
directly proportional to the amount of integration as measured by either BSD viral
transduction or Alu-PCR assay. Therefore, the lack of integration is best explained by
defects at the initial 3’ processing step, a step required subsequently for stand transfer and
completion of integration. Furthermore, it appears that any molecule that is processed is
competent for the strand transfer reaction—3’ processing being the limiting step in these
mutants. A corollary to this fact is that mutant DNA must be processed at both ends of a
given molecule to be a valid substrate for the subsequent strand transfer reaction. Finally,
the residual catalytic activity of IN 270, 271 and 272 might be sufficient to avert the
over-accumulation of 2-LTR circles observed in the overtly catalytic defective D116A
mutant, perhaps with enough activity to skew the fate of reversed transcribed DNA into
an increased quantity of 1-LTR circles. Alternatively, since these truncations (IN 270,
271 and 272) possess intact active sites, the IN molecules, though unable to conduct 3’
processing, may remain tightly bound to the viral DNA ends, thus occluding them from
DNA ligases that would otherwise efficiently ligate the blunt-ended DNA to produce 2LTR circles.
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Figure 24. 3’ processing of IN truncation panel. Processing of the viral DNA was
measured at the 5’ LTR in infections of a subset of the IN truncation panel. The results
are shown in (A), with the values adjusted to a WT rate set at 100. The DNA samples
used for this experiment were also quantified for the levels of late RT product, the results
of which are displayed alongside the processing levels. (B) The levels of processing are
adjusted for the amount of late RT product in the cell.
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Summary/DiscussionThe BSD integration experiment (Figure 17A) indicated a detectable yet almost
negligible catalytic activity for mutants IN 270, 271, 272, but from this experiment,
which ultimately measures IN-mediated strand transfer activity, it is impossible to gauge
the efficiency of 3’ processing. Though not commonplace, there is precedence for an IN
mutant (IN S119D) that efficiently processes viral DNA, but is drastically deficient for
strand transfer activity. In terms of 1- and 2-LTR circle production, the resemblance
between the Class I mutants (IN 270, 271 and 272) and the flanking, replicationcompetent truncations (IN 269 and 273) is undeniable, and thus prompted us to examine
in more detail the mechanics of the integration reaction in these viruses. These
experiments were driven in part also by the hypothetical notion that processed,
unintegrated viral DNA is preferentially manifested as 1-LTR circles, which by Southern
blot analysis were observed at similar abundance in the Class I mutant truncation group
and the immediately flanking mutants. The subsequent analysis of the 3’ processing
efficiency did not support this hypothesis since significant processing was not occurring
for these mutant. Indeed it was found that Class I truncation mutants, IN 270, 271 and
272 are significantly defective (but not completely) for 3’ processing, the first catalytic
step of integration. If this is due to an inability to bind to the viral DNA, or if complexes
required for catalysis are no longer able to form or other reasons is not currently known,
but are subjects for further investigation.
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Class II Truncated IN Mutants

We next sought to elaborate our initial ‘RT-defective’, Class II designation of the
IN 260, 265, 266, 267 and 268 (IN 260-268) mutant set to ascertain the nature of the
affected viral processes. Given that these mutants were profoundly defective for reverse
transcription, we evaluated these mutants for defects in post-integration events.
Establishing proviral transcription and protein synthesis as a starting point for the sake of
description, the first viral process that is susceptible to IN perturbation is assembly, the
process whereby components for the manufacture of virions are amassed at the plasma
membrane as a prelude to budding. One symptom of perturbed assembly is a decrease in
the efficiency of viral release which can be evaluated by the level of p24 capsid antigen
or reverse transcriptase activity in the cell-free supernatant from transfected or infected
cells. A gradual diminution of viral release was in fact observed with decreasing IN
length (data not shown), indicative of escalating assembly defects. There was, however,
little difference between Class II IN mutants and the proximal viable IN 269 virus and the
other Class I mutants described above. The next step that can be affected by mutant IN is
with regard to the precision of virion particle formation. This defect can be traced to
assembly defects, which can misdirect the incorporation of viral components to the virion
as it buds. The resulting virions might then display aberrant morphologies, and could be
intractable to maturation. Finally, the reverse transcription step is subject to IN-mediated
perturbation, either in a direct or indirect fashion. Eliminating any discernable defects at
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assembly/maturation can readily identify viruses that are specifically blocked at the step
of reverse transcription that are observable during a new round of target cell infection.

INTRAVIRION ANALYSIS:
We conducted the investigation of the nature of the block in the Class II mutants
by sequentially backtracking from the reverse-transcription step. We first examined the
protein content of the released viral particles, to determine if there was any mispackaging
of viral precursors. Poor incorporation of the Pol products, which include RT and IN,
could potentially account both for inefficient reverse transcription and subsequent
integration. Viral supernatants were filtered, normalized for p24 content, and pelleted
through a 25% sucrose cushion. The virus pellets were then lysed and analyzed by
western blot analysis using antibodies targeted to specific HIV proteins. The result are
shown in Figure 25.

ResultsTo substantiate the comparison between levels of intravirion protein content, we
ensured that a similar fraction of virions were loaded into each well by probing for the
p24 protein, CA, which constitutes the proteinaceous coat of the viral core. The levels of
CA are similar in each sample, and little of the p55 Gag precursor or its p41
intermediates were detected, indicating that processing within the virions appeared
normal. However, when these blots were subsequently probed for the Gag-Pol products
RT and IN, there appeared to be distinct differences between viruses. The levels of IN
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and RT incorporation is significantly curtailed in the IN 212, 260, 265, 266 and 267 (IN
212, 260-267). This may account in part for the defect of reverse transcription product

Figure 25. Analysis of virion protein content. Viral supernatants adjusted for p24
content were spun through a sucrose cushion to pellet virions, which were then disrupted
and the lysates probed by western blot analysis for intravirion levels of RT, IN and CA.
The amino acid sequence of IN is shown at the top.

formation in mutants IN 212, 260-267. It cannot however be discounted that these IN
molecules may also be specifically defective for supporting RT. A Pol packaging defect
appears to not be the case for IN 268, however, since normal levels of both RT and IN are
found in this virus, and this pattern is maintained as expected for the rest of the mutant IN
truncation set and the WT virus. Therefore we can tentatively establish that IN 268 is a
mutant that is specifically blocked at reverse transcription. However, further analysis of
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polyprotein processing and virion maturation of IN 268 is required to give further
evidence for this supposition.
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INTRACELLULAR POL PROTEIN LEVELS:
As previously demonstrated, mutation within HIV-1 IN can result in premature
activation of the viral protease (PR) that ultimately leads to assembly defects [47].
Premature Gag and Gag-Pol precursor polyprotein processing can result in the unnatural
accumulation of the mature Gag and Gag-Pol constituent proteins within the cytoplasm.
We looked for evidence of this phenomenon in the Class II IN truncation mutants by
conducting Western blot analysis of the intracellular protein content of transfected cells.
Initially, we investigated the Gag-Pol profile, by probing for two of its processing
products, RT and IN.

ResultsThe observed intracellular RT levels provide little indication of overt processing defects
(Figure 26), as the p66 and p51 RT subunits were detected at approximately similar
levels across the viral panel. A slight discrepancy in the RT signal can be detected in the
panel to the right, where a side-by-side comparison of ΔIN, IN 212 and IN 260 with the
WT is accommodated (these mutants may contain slightly elevated levels of the RT
subunits). Other than this slight discrepancy, the RT levels were not overly dissimilar.
This, however, is in contrast to the observed IN protein levels, where it was discovered
that the Class II mutants, inclusive of IN 268, displayed a significant reduction of
intracellular IN. The reason for this was unclear at this moment, but if premature
processing was occurring, then the mature IN removed from its protective
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Figure 26. Intracellular levels of Pol products. Lysates of cells transfected for 48 hours
with IN truncation plasmids were resolved by SDS-PAGE, and probed for the
intracellular levels of RT and IN. A longer exposure is shown in the lower panel to allow
detection of the IN protein.

association as a Pol fusion product, would be expected to be degraded in the cytoplasm.
There was a second discrepancy between the individual samples, and this was in
the level of some of the intermediate-sized products that ran just below the unprocessed
Gag-Pol precursor. Compared to WT, IN 268 is the first truncation to display a WT level
of these products. IN 212, and 260-267, contrastingly, displayed minute amounts of these
products. It is obvious that it is some form of the Gag-Pol precursor, since they are being
detected by antibodies against RT and IN. The next question was whether these
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represented degradation products of Gag-Pol, or alternatively, intermediately-processed
species produced by cleavage via the viral PR.
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INTERMEDIATES:
A consequence of probing the intracellular blot with monoclonal α-IN and α-RT
antibodies is the detection of the native Pr160Gag-Pol polyprotein and several intermediate
products, as visualized in Western format in Figure 26. The disparity in abundance of
these intermediate products among the IN truncations prompted further investigation to
determine their origin, and the reasons why they are found in such low quantities in the
Class II mutants IN 212, and 260-267. The specific sizes and pattern of the bands in each
virus suggested that these were not haphazard degradation products of the Gag-Pol
precursor, but rather are specific, partially processed intermediates of the precursor. As
such, they would be produced by the specific cleavage action of the viral PR.
We treated transfected cells with a high concentration of the potent and specific HIV-1
protease inhibitor, Ritonavir, and observed the influence of PR inhibition on the levels of
the intermediate products. We tested this on four viruses: IN 266 and 267, both
representative Class II mutants that contained diminished levels of the intermediate
products; IN 269, a replication competent virus that displays a WT pattern of
intermediate product formation; and the WT virus, to observe the normal profile in both
the presence and absence of the drug. The results are shown in Figure 27.
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ResultsIn the absence of Ritonavir (Figure 27, lanes 1 through 4), the intermediate
products can be clearly detected, and the previously witnessed disparity in their levels
between the individual viruses is observed here once more. Similarly, the distinct levels

Figure 27. Gag-Pol intermediates are produced by HIV-1 protease activity. The class
II mutants IN 266 and 267, and replication competent IN 269 and 288 (WT) plasmids
were transfected into 293T cells, in the presence or absence of the PI Ritonavir. Whole
cells lysates were collected 48 hours post transfection, and probed for IN in Western blot.

of mature IN are identical to those observed in the previous experiment (Figure 26). With
the addition of inhibitor, administered far in excess of the nanomolar range that normally
inhibits HIV-1 PR, the intensity of the intermediate products in each virus is significantly
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reduced, and the free form of IN becomes undetectable. There is also a clearly
perceivable increase in the level of the unprocessed precursor especially in the mutant
viruses, which is expected when proteolytic processing is inhibited. It is therefore
apparent that the intermediate products are in fact bona fide, partially processed
fragments of the Gag-Pol precursor.
Close inspection of the small quantity of intermediate products that are produced
in the presence of the drug divulges another difference in the Class II mutants. There is
the preferential accumulation of a larger than normal molecular weight intermediate
(compare Figure 27 lanes 5 and 6 with lanes 7 and 8). Proteolytic processing of the GagPol precursor is not random, but rather is orchestrated through a specified and sequential
pattern of cleavages [189, 190]. The addition of the PR inhibitor, as in this experiment,
affords the opportunity to observe the initial cleavage reactions of Gag-Pol [49]. The
results shown here indicate that in the IN 266 and 267 mutants, the precursors are not
only processed prematurely, but also display an aberrant pattern of cleavage.
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INTRACELLULAR GAG PROCESSING:
Having identified the intracellular profile of the Gag-Pol precursor, we next
investigated the intracellular profile of the Gag polyprotein precursor, probing with an
antibody raised against the viral capsid (CA). The range of products this antibody will
detect is far less diverse than those for IN and RT antibodies, highlighting only the
Pr55Gag precursor, the p41 and p25 intermediate species, and the mature p24 CA.
Previous studies conducted in the lab demonstrated that the Gag processing profile
pattern of overt Class II mutants and WT viruses tend to converge over time towards the
WT phenotype, thus masking mutant defects using the Western blot format. However,
harvesting relatively early after transfection (12 hours post transfection) can easily
distinguish those viruses that display Gag processing defects. The panel of IN truncations
were transfected and harvesting at 12 hours post transfection, the lysis conducted in the
presence of Ritonavir to prevent any further possible precursor processing during or after
lysis. The results are shown in Figure 28.

ResultsThis analysis revealed that though the levels of Pr55Gag and of the p41
intermediate species are similar throughout the panel of IN truncations, the Class II IN
truncation mutants (IN 260, 265-268) displayed an irregular p24:p25 ratio, similar to that
observed in a virus with gross deletion of the IN region (IN 212, Figure 28, lane 2), itself
a well-documented processing defective Class II mutant [47]. The overabundance of the
p25 intermediate in relation to p24 has been previously noted as a surrogate marker, a
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symptom of premature processing [191], its presence here confirming the premature
processing inclination in these viral mutants. The WT virus, as to be expected, displays
the most precise control over its processing, exemplified by comparably low levels of p41
and p24. Thus, with the exception of IN 268 in which only one element of processing
defects was observed, the Class II IN truncation mutants appear to be impaired primarily
at assembly, due to an abnormality of intracellular polyprotein processing induced
ostensibly by disregulation of viral protease activation.

Figure 28. Intracellular Gag processing of IN truncations. Lysates of cells transfected
for 12 hours with IN truncation plasmids were resolved by SDS-PAGE, and probed for
the intracellular levels of CA, which detects an epitope present in the mature Gag
precursor, the p41 and p25 intermediates, and the mature CA (p24). As a loading control,
blots were reprobed with γ-tubulin antibody.
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Summary/DiscussionThe viral process most vulnerable to loss of control over precursor processing is
assembly, since it reliant upon the various biochemical actions of the full-length
polyprotein precursors. Assembly defects then directly impact the efficiency of virion
output, and the precision of virion composition and architecture. Previous studies have
demonstrated that viruses produced with IN deletion or mutation display aberrant
intracellular precursor processing profiles, decreased virion release, and produce
abnormal viral particles [47, 107]. However, some of these studies usually entail sizable
deletions, or almost complete ablation of the IN region. The work presented in this thesis
is the first to demonstrate precisely the minimal length of IN at which control of
polyprotein processing occurs (IN 269), which is coincidentally the length at which all IN
functions are restored, albeit at significantly attenuated levels.
Analysis of the Class II mutants was very informative, especially with regard to
the distinct behavior of IN 268. With the original categorization of the IN 260, 265-268,
it could not be ascertained at which stage the block existed. As we sequentially
backtracked from the common reverse transcription block, initially we discovered that the
truncation Class II mutants displayed distinct abilities to package the products of the pol
gene. The appendage of the isoleucine at position 268 (IN 268) bestowed appropriate
packaging of both RT and IN, indicating that the Pol precursor is efficiently packaged
into virions. In contrast, IN 212, 260-267 (IN 212-267) contain significantly lower
quantities of Pol products on a per virion basis. The reason for the virion protein
discrepancy became clear when Western blot analysis of the levels of the intracellular
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constituents of Pol were scrutinized. We found a clear disparity in the steady-state levels
of the unprocessed Gag-Pol precursor and its partially-processed species. IN 268
displayed a near WT pattern of the partially processed precursors, whereas the other
Class II mutants were significantly deficient in these products. Since we were probing
against the RT and IN domains which are located at the extreme C-terminus of Gag-Pol,
the partially-processed Gag-Pol species represent precursors that have had one or more
N-terminal Gag domains removed. It has been reported that a Gag-Pol precursor lacking
most of the Gag domain can be efficiently packaged into virions independently of GagGag interactions, but via interactions between the RT domain of the truncated Gag-Pol
precursor and the NC domain of the Pr55Gag precursor [192-194]. This phenomenon
would then likely account for the ability of IN 268 to incorporate normal levels of Pol
products into virions.
The low cellular levels of the Gag-Pol precursor, its intermediate products, and
the mature IN in mutants IN 212-267 are indicative either of decreased Gag-Pol
synthesis, degradation of the Gag-Pol precursor, or abnormally rapid or aberrant HIV-1
protease cleavage. The first two theories are not likely, since we detected normal to
slightly elevated levels of intracellular RT, which is produced by PR-mediated Pol
cleavage. The paradoxically low intracellular IN levels can be explained by the fact that
cytoplasmic IN, unlike RT, is subject to rapid proteasomal degradation via the N-end rule
pathway [195] (for review see [196]). This phenomenon would explain the discrepancy
between the levels of cytoplasmic RT and IN. It is possible also, that these IN truncations
could be unstable due to improper folding of the CTD, in which case it would also be
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targeted for degradation. This question is investigated in the subsequent section. In either
scenario, the low levels of IN actually support our hypothesis that the IN 212-267, and IN
268 mutants harbor prematurely processed precursor proteins.
The IN 268 mutant packages normal levels of Pol products into the virion, and
contains near normal levels of intracellular partially processed Gag-Pol, but it does
display two signs of processing defects. These include the low intracellular IN level, and
an aberrant p24/p25 ratio. This mixed phenotypic display indicates that IN 268 may
possess a vestige of the necessary function required for controlling precursor processing,
an activity that is lost with the removal of additional residues.
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Functional Studies of IN Truncations

INHERENT STABILITY OF IN TRUNCATIONS:
The natural amino-terminal residue of HIV-1 IN, produced by viral PR cleavage
of the Gag-Pol precursor, is phenylalanine (F). This residue, in conjunction with
undefined internal signals within IN, targets the protein for rapid proteasomal degradation
by the specialized N-end rule pathway [195]. In the normal course of the viral replication,
IN is protected from this pathway by its translation as a covalent adjunct to the Gag-Pol
precursor, in which form it is targeted to the sheltered environment of the virion before
being released in its mature, processed F-form. It is then afforded further protection
during the cytoplasmic transit of the PIC by its intimate associations within the
macromolecular complex of the PIC. Mutant viruses that induce premature cleavage of
the viral precursors in the cytoplasm of the producer cell would be thought to release free
mature IN into the cytoplasm, where it would be subject to expeditious degradation. Such
appears to be the case for a subset of the IN truncations, already classified as Class II
mutants (IN 212, 260, 265, 266, 267, 268). Indeed, inspection of the intracellular protein
profile of these particular truncations reveals significant diminution of cell-associated IN
(Figure 26, lanes 1 to 5, compare to lanes 9 to 10). In this case, however, N-end
degradation may not be the sole method by which IN can be degraded. As we were
manipulating the protein within an ordered region in the SH3 fold, a natural consequence
could be that the domain loses the ability to conform to a naturally-ordered structure.
Misfolded proteins are also naturally targeted for degradation by the cellular proteasome.
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To resolve the question of whether these IN Class II truncations are being targeted to the
N-end rule pathway, or are inherently unstable due to improper folding, we investigated
the steady-state intracellular levels of N-end rule pathway-resistant IN truncations. As
members of our lab have demonstrated, changing the natural N-terminal amino acid to
methionine (M) significantly enhances the stability of IN, allowing the protein to be
detected far more readily [195]. In this experiment, IN and eGFP are co-expressed from a
single bi-cistronic mRNA, a 3’-positioned internal ribosome entry sequence (IRES)
providing for the expression of eGFP downstream from the IN sequence. eGFP levels,
detected by western blot, serve as the internal control for side-by-side comparisons of IN
levels. The results are shown in Figure 29.

ResultsThe western blot in Figure 29 shows the steady-state levels of both eGFP, serving
dual roles of a loading and expression control, and a small panel of our IN truncations. A
subset of these was observed to have significantly diminished cytoplasmic levels in
producer cells. To distinguish between their degradation by the specialized N-end rule or
the misfolded protein pathways, we made N-end rule resistant recombinant IN molecules
by appending a protective Met residue (M-form) to the N-terminus. As the Western blot
clearly demonstrates, the steady-state levels of each IN truncation are nearly equivalent
for IN 265, 267 and 268, with only IN 260 and 266 displaying decreased IN levels,
indicating that these two truncations maybe unstable. Though this is only a snapshot of
the individual protein levels, and does not divulge of the respective half-lives of the
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truncations, there appear to be little difference in the steady-state levels of the IN 267 and
268 truncations compared to WT IN. This indicates that blatant misfolding of the CTD
may not explain the observed low cytoplasmic levels of IN in virus producer cells.
(Figure 26).

IN
GFP

Figure 29. Stability of M-IN. Methionine-initiated IN truncations were tested for
cytoplasmic stability. eGFP and IN are translated from a bi-cistronic transcript, and so the
levels of GFP serve as an internal control for the levels of IN.
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D116A COMPLEMENTATION OF IN TRUNCATIONS:
A possible explanation for the observed phenotypes of the progressively deleted
IN CTD mutants is simply that the enzyme becomes increasingly unstructured and
misfolded as it is gradually shortened. This is especially pertinent when removing
residues past IN 270, the outer margin of the single structural element in the CTD, the
SH3-like fold (Figure 7C). Indeed, in our panel of mutants, IN 268 and shorter are the
only mutants that exhibit multiple defects in viral dynamics. If in fact the pleiotropic
effects observed after truncating past 269 are caused by the loss of one or more specific
CTD-contributing activities, and not by gross protein misfolding, then those activities
could potentially be supplied in trans by another IN protein that has an intact CTD. We
thus tested the IN truncations in a reciprocal rescue scheme with the IN D116A mutant,
which contains a mutation in the CCD, but has an intact CTD. Interdomain
complementation is a commonly used methodology to discriminate pair-wise patterns of
IN dependency, due to the integration reaction requiring distinct roles from participating
monomers. In one model based on recent CCD-CTD crystallographic data, the viral DNA
processed end is in complex with the CCD of one monomer while the same viral DNA is
coordinated by the CTD of the opposing IN monomer (Figure 10). The IN truncation
mutants possessing a properly-folded and thus catalytically active CCD, should
complement the D116A IN, and in turn the D116A IN with its intact CTD should
complement the replication defective CTD truncation mutants. Hybrid IN viruses made
by co-transfection of mutant plasmids were tested for integration frequency and in vitro
3’ processing activity. The results are shown in Figure 30.
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ResultsThe integration frequencies of the single and hybrid viruses are shown in Figure
30A. The single viruses each displayed a rate of integration per p24 unit similar to that
previously observed. For example, IN 266 and 267 have no detectable transduction
ability, while IN 269 and IN 273 are capable of more than 10% of the WT rate with the
intervening IN 270-272 viruses being severely attenuated. When co-transfected with an
IN D116A viral plasmid to make hybrid IN viruses, a clear demarcation between viruses
that could or could not be efficiently rescued for integration was established. IN 266 and
267 were rescued by IN D116A, but only minimally, achieving 14 and 7% WT
transduction rates respectively. Contrastingly, IN 268 was rescued by IN D116A very
efficiently, approaching the WT level of transduction efficiency. The Class I mutants IN
270-272 were also efficiently rescued by IN D116A, likewise attaining WT transduction
efficiency.
The efficiency of processing at the one end of the viral DNA (5’ LTR) was then assessed;
the results are shown in Figure 30B. In the single viruses, the efficiencies of processing
are as they were previously determined (compare with Figure 24). Based on the
complementation data for the BSD integration assay, mutants IN 266 and 267 were
expectedly and significantly rescued by D116A for processing, but only minimally. IN
268 however displayed in this assay, as in the BSD assay, abundant integration activity in
the presence of IN D116A. Notably, the 3’ processing reaction in the IN 269 and IN 273
hybrid viruses was significantly enhanced by the IN D116A mutant, achieving an
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approximately 5-fold increase compared to the 3’ processing rate encountered in the
uncomplemented viruses.
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Figure 30. Complementation of IN truncations with the CCD Class I IN D116A
mutant. One-step single or hybrid viruses made by cotransfection of the virus expression
plasmids for the IN truncations or IN D116A were tested for integration reaction activity
in the BSD integration assay (A), and for efficiency of 3’ P (B). + = Hybrid D116A virus.
- 126 -

ATTEMPTED RESCUE OF IN 267 AND IN 268 WITH CLASS I CTD
TRUNCATION MUTANT:
It was established in the previous experiments that the canonical Class I mutant,
IN D116A, effectively rescues IN CTD truncations from both phenotypic classes: IN 268
(Class II), 270, 271 and 272 (Class I). While these Class I mutants are clearly rescued for
a defective integration activity, the basis for IN 268 rescue is ambiguous. The IN 268
mutant cannot facilitate efficient reverse transcription, but we cannot extrapolate from
this that it is also defective for integration activity. IN D116A rescues the reverse
transcription defect of IN 268 (data not shown), but is it necessarily assisting IN 268 also
for integration? It is possible that given a cDNA substrate, IN 268 can proceed efficiently
with integration without any form of complementation.
Class I IN mutants located within the CTD are uncommon, but our studies have
led to the identification of three examples, all consecutive truncation mutants: IN 270,
271 and 272. These mutants offer a unique opportunity to study the rescue of the reverse
transcription defect of IN 268 but without their contribution to- or complementation ofintegration. If the isolated IN 268 is integration defective, its mutation, being harbored in
the CTD, will require a distinct IN bearing an intact CTD for rescue. To investigate this
possibility IN 267 or 268 viral plasmids were co-transfected with the Class I IN 270
mutant viral plasmid to make hybrid viruses, which were tested for successful
complementation by measuring transduction efficiency in the BSD assay. The results are
shown in Figure 31.
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ResultsIt was previously shown that packaging a catalytically-inactive IN into virions is
sufficient to rescue the RT defect of IN Class II mutants [172], a finding that we have
corroborated (data not shown). We co-transfected IN 270 with IN 267 or 268 to
determine if the contribution of reverse transcriptase activity was sufficient to rescue
these Class II mutants. The results (Figure 31) clearly indicate that neither IN 267 nor
268 can be rescued simply by co-transfecting an IN that supports reverse transcription.
Thus it appears that the nature of the disruption of the CTD in IN 268 affects not only the
majority of secondary IN functions, but also of the primary integration functions.
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Figure 31. Complementation between Class I and Class II IN truncations. Hybrid IN
267/270 and IN 268/270 viruses were tested for successful complementation in the BSD
integration assay. Full-length IN virus (WT) was used as a positive control. Inoculated
cells were split into selection in consecutive wells at decreasing densities.
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INTERACTION OF IN WITH LEDGF:
LEDGF/p75 was first identified as a cellular binding partner of IN by coimmunoprecipitation [167], and the interaction was subsequently confirmed in a yeasttwo hybrid assay ([140]. Disrupting the interaction by siRNA knock-down of endogenous
cellular LEDGF or by mutating key residues within the LEDGF binding site in IN results
in several-fold defect in transduction ability, the block identified as occurring at
integration [197]. Studies indicate that the IN-LEDGF interaction plays several potential
roles including nuclear import of the PIC, tethering IN to the chromatin and enhancement
of IN catalytic activity [140, 197, 198]. The interaction is mediated via residues within
the IN catalytic core, and a single amino acid substitution (Q168A) in this domain can
abrogate the interaction. The role of LEDGF as a chromatin tether for IN is particularly
apparent during mitosis, wherein IN is found intimately associated with the condensed
chromosomes. This chromatin staining by IN is lost in cells that lack LEDGF, or with IN
mutants harboring the Q168A mutation that abrogates LEDGF interaction.
Since the IN-LEDGF interaction is a well-characterized and essential
phenomenon, we tested the ability of a subset of our IN truncations, in the context of Cterminal fusions of eGFP, to stain condensed mitotic chromatin, using this as a visual
marker for LEDGF interaction. It was hoped that this line of inquiry would give an
inclination as to the overall structural integrity of the truncated enzymes, that an INLEDGF interaction mediated by IN CCD residues should not be disturbed by CTD
mutations, unless those mutations exert global effects on the mutant protein. The results
are shown in Figure 32.
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Figure 32. IN truncation and LEDGF interaction. eGFP-IN truncation fusions were
transfected into 293T cells, fixed 12 hours post transfection, mounted onto slides, and
observed for chromatin binding, a surrogate marker for LEDGF interaction.
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ResultsThe association of HIV-1 IN with mitotic chromatin is a surrogate marker for
binding to LEDGF, which acts as a molecular tether between chromatic DNA and IN. A
subset of IN truncations was fused at the N-terminus to eGFP and then assayed for the
ability of the eGFP-IN fusion to adhere to mitotic chromatin. The LEDGF interaction
with IN is mediated by residues in the catalytic core of IN, and it is thus unlikely that this
association would suffer from a CTD mutation. LEDGF-IN association if disrupted,
however, may be indicative of global protein effects. This line of inquiry is part of our
effort to ascertain the specific defects of these IN truncations.
The results in Figure 32 demonstrate that some of the IN truncations (IN 260, 265,
and 267) displayed a chromatin staining pattern similar to the LEDGF-binding mutant,
IN Q168A. In the GFP channel, a shadow can be discerned where the condensed
chromatin is positioned. This so-called negative staining is indicative of a lack of
chromatin association, and by proxy, a lack of LEDGF binding. The first truncation to
display consistent chromatin binding was IN 266, suggesting that this mutant can
functionally associate with LEDGF. The next truncation, IN 267, however, formed large
cytoplasmic aggregates that demonstrated no affinity for condensed chromatin. The next
truncation IN 268, and the remainder, IN 269, 270, 271, 272 and 273, were all found to
bind chromatin, though the level of binding intensity displayed by full length IN was only
consistently observed in IN 273. In some cases, we could however find a few examples in
which IN 269 or 270 fusions did not appear to be associating with the mitotic chromatin
(data not shown). This discrepancy at this time cannot be accounted for. It would be
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instructive in future experiments to test each truncation in the background of the Q168A
mutation, which may serve to dispel these ambiguities.
In summary, we discovered that eGFP-IN 266 and 268-273 bound to condensed
chromatin during mitosis, indicative of LEDGF-binding, whereas IN 260 and 265 did
not. IN 267 displayed a more drastic defect, producing cytoplasmic aggregates that may
deter DNA binding. These results provide more support for IN 268 being the minimal
length of IN after which secondary IN functions are constrained.
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Selection of Tail-less Second Site Revertant Viruses

HIV-1 is a highly adaptable virus, evolving rapidly in the face of selective
pressure to constantly achieve the fittest form within the context of a given biological
environment. It is facilitated in this regard by the large number of progeny, its rapid
replication rate, and perhaps most significantly by the error-prone nature of its genomic
replication. These features form the basis for the ease with which the virus constantly
evades the dynamic adaptive immune responses of the host, and for the genesis of drug
resistant viruses in patients. In tissue culture, however, this aspect of HIV-1 has been
indispensible for studying the mechanisms of antiviral drug mechanism and inhibition,
and for eliciting the significance of viral sequence and structural elements. Selective
pressure can be applied externally in the form of suboptimal concentrations of antiviral
drugs, which permits a low level of viral replication and thus the accrual and subsequent
selection of fitness-enhancing mutations that confer drug resistance. Selective pressure
can also be applied internally by introducing mutations into areas of the genome that
attenuate viral replication. Often the virus simply reverts to the wild-type sequence, but
sometimes second site mutations can arise which can restore viral replication. Such
studies have been successfully applied to deciphering the relevance of RNA secondary
structures in the TAR element, and for identifying hidden intraprotein interactions.
As a means of understanding the function of the IN tail, we used this technique of
forced evolution to elicit second site revertants in a tail-less IN mutant. We used the IN
269 stop mutant in these selection experiments, since it is completely devoid of the
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unstructured tail, and as we have demonstrated is capable of sustained, albeit significantly
attenuated replication. The sluggish replication kinetics of the founder virus supplies the
impetus for the selective advantage and outgrowth of any fit variants that may arise. To
encourage the genesis of second site revertants, we ensured that reversion to the wildtype sequence would be unlikely, by introducing five stop codons after the 269 residue:
three in the IN reading frame, and one in each of the two overlapping reading frames
(Figure 33). The CEM cell line was selected as the tissue culture system through which
the virus would be passaged for several reasons. Firstly, these cells are grown in
suspension, and as such are amenable to maintenance in large cultures that can achieve
high cell densities. This effectively provides large numbers of cellular targets for multiple
rounds of infection, thus favoring the accrual of random mutations. Secondly, these cells
are permissive, not requiring Vif function for productive infection, and thus eliminates
any possible concern engendered by the unintentional disruption of the vif ORF created
by the introduction of the five stop codons. Finally, the outgrowth of revertant viruses can
be readily perceived by conventional microscopic detection of a sudden uncharacteristic
burst of robust syncytia formation.
The five-stop codon IN 269 sequence [IN 269 (5x)] (Figure 33) was engineered
into two proviral constructs. The first construct encoded functional viral proteins except
for Vpu (Vpu-). A vpu- background was warranted since vpu- viruses proliferate more
efficiently and create syncytia more readily in CEM cells than their vpu+ counterpart
(data not shown). This may be due to an enhancement of cell-cell transmission by the
accumulation of virus particles on the cell surface. The second proviral construct has a

- 137 -

frame-shift mutation within the vpr gene such that the Vpr protein is unstable and
effectively absent intracellularly; all other genes are intact in this construct including vpu.
Vpr was disrupted in this virus to prevent cell cycle arrest of infected cells and to allow
viral proliferation and spread. This virus is predicted to spread preferentially by the free
virus route, rather than through cell-cell contact. CEM cells were infected with a low
inoculum and subsequently passaged at regular intervals. At every fourth or fifth split, the
infected cells were massed by centrifugation and the cell-free supernatant containing cellfree virus transferred to fresh, uninfected CEM cells. Occasional cell-free transfer of
progeny virus to uninfected cells was done so as to increase the likelihood of selecting
revertant viruses while culling out unfit viral species (i.e., cell-cell transmission might
favor the persistence of the attenuated founder virus). The scheme is shown in Figure 33.
Robust syncytia formation was detected approximately four months after the
initial infection with the first virus (vpu-) and approximately one month later for the
second viral construct (vpr-). Total DNA from a portion of the culture was then harvested
at weekly intervals and regions of interest were amplified by PCR, and the DNA
examined by bulk PCR sequencing. Although chromatographic DNA sequencing of an
aggregate PCR product from a diverse viral population under growth selection will only
detect major alterations (reliably >20% deviation), we were fortunate to uncover a
predominant codon altering substitution mutation as well as less representative but linked
substitutions that changed the IN amino acid sequence (Figure 34). To test for the validity
of the revertant phenotype, mutagenic primers were designed to assemble test proviral
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constructs that were isogenic for all viral sequences except at the relevant, revertant
locus.

IN 269 (5x) stop virus
Passage cells every 5-6 days, transfer
viral supernatant every 3-4 passages
Robust syncytia
production

IN 269 (5x) Stop virus

Harvest DNA

PCR amplify IN region

Sequence or
reconstruct into
otherwise WT proviral
clone

Figure 33. Selection of viral revertants. Schematic of the procedure used to procure
viral revertants of the IN 269 stop virus. To prevent reversion to WT length, five stop
codons were introduced after the 269 codon, two in alternative reading frames, and two
extra ones just after the first, with one eliminating the 273 residue.
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Figure 34. Outgrowth of revertant second site mutant viruses. The IN gene from viral
DNA procured from infected cultures was PCR amplified and sequenced. A. and B. are
derived from one infection that was split into two flasks, and followed in parallel. The
C56Y mutation was likely present prior to the flasks being split. Flask B showed sign of a
second mutation, I60T. The lower panels are a snapshot of the sequence of viral
population taken four weeks after the top panels.

ResultsAfter four months in culture, robust syncytia formation was detected
microscopically in cells infected with the Vpu- founder virus. This culture was then split
into two flasks, designated ‘A’ and ‘B’. These were monitored for sustained syncytia
formation, and at various time points the IN region was amplified and sequenced. Two
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such time points, taken four weeks apart, are shown in the chromatogram traces in Figure
34. The presence of one subpopulation could be readily detected in flask A, whereas two
subpopulations were detected in flask B. These correspond to non-synonymous
substitutions creating the missense mutations, C56Y and I60T. In an effort to detect the
presence of less prevalent mutations, the PCR amplified IN region was subcloned back in
the virus plasmid backbone, transformed to bacteria, and the individual clones screened.
The list of mutations from individual clones is shown in Table 1 and the frequency with
which they were obtained. As expected, the majority of the clones contain the
predominant mutations C56Y and I60T, but other mutations were also revealed.
Remarkably, despite the detection of a sudden enhanced rate of syncytia formation, the
vpr- founder virus culture displayed no apparent heterogeneity within the IN coding
region, Instead, a stop codon was detected at position 22 within the vpu gene and perhaps
an ancillary mutation within the tat gene at its 3’ splice site. It is not known if these two
mutations are present in the same viral genomes, or represent two distinct populations.
Although the significance of the tat mutation has yet to be investigated, the selection for
the vpu- virus is indicative of the relevance of Vpu for viruses growing in CEM cells.
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Table 1. Identification of potential revertant viruses. IN, Tat, Vpu, Nef regions and 2LTR junctions from revertant viruses derived from Vpr+Vpu- or Vpr-Vpu+ cultures were
PCR amplified, cloned into the parental viral plasmid, and sequenced. The nonsynonymous mutations discovered are listed with the frequency with which they were
detected in unique clones
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Analysis of Revertant Viruses:
Replication competencyPresent in the list of possible revertant viruses are several viruses containing
multiple substitutions. These can be authentic revertant viruses, or potentially, these
mutation combinations could be artifacts of recombinatorial events between distinct viral
sequences that occur either during reverse transcription in the tissue culture dish, or
during PCR amplification. We only tested the potential revertant mutations in the
combinations as they were discovered, however. We intend to investigate each of these
mutations in isolation in the near future. The viruses were tested for improved fitness in
side-by-side comparisons with the founder IN 269 (5x) stop virus in the syncytia
formation assay, and against WT virus, using a range of initial inoculums. The results are
shown in Table 2.

ResultsThe only mutations that measurably improve the fitness of the tail-less IN mutant
in the syncytia formation assay are the C56Y and I60T mutations. These viruses were
further characterized in efforts to understand how IN 269 was improved for replication
competency by each of these additional mutational alterations.
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Table 2. Testing the replication competency of possible revertant clones.

Mutant

Replication
competency

C56Y

+++

I60T

+++

K14R C56Y

+++

C40R C56Y

-

C56Y G140E

-

C56Y Q164R

-

C56Y Y194C

-

C56Y Q148Q S153T

-

I60T C56Y M154I

-

E13K C56Y G82E E157K

-

269 5x (Parental)

+

WT

+++++
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Characterization of C56Y and I60T Reversion Mutations:

Site-directed overlap PCR mutagenesis was employed to combine either C56Y or
I60T with IN 269 and the resultant viruses (C56Y/IN 269 and I60T/IN 269) examined for
the efficiency of 3’ processing (8 hpi), the production of 2-LTR circles (24 hpi) and the
relative efficiencies of the reconstituted mutants in the BSD transduction assay. The
results are shown in Figure 35.

ResultsThe results of the three assays are shown in Figure 35. In each case it is evident
that both of the revertant mutations C56Y and I60T greatly enhance the fitness of the IN
269 truncated, tail-less virus. The basis for the rescue can be readily detected at the 3’ P
reaction.
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Figure 35. Rescue of tailless IN catalytic activity by second site revertant mutations.
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Summary/DiscussionWe have successfully selected two intragenic second-site revertant viruses that
have regained a significant level of fitness in the IN 269 ‘tailless’ background. These
mutations (C56Y and I60T) substantially improve the 3’ processing efficiency of the
parental, truncated IN 269 virus. This then ostensibly facilitates an increase in
transduction efficiency, and an attendant diminution in the production of 2-LTR circles, a
further indication of the improved catalytic function. Though there were fourteen
mutations that were generated, only two, C56Y and I60T display observable
improvement in replication competency.
The most remarkable discovery in this experiment was that the majority of the
mutations that were generated mapped to the catalytic core of IN (Figure 36). Further
validating their significance is the fact that these mutations were all clustered on the
solvent-exposed face of a monomeric subunit in the dimeric crystal. The only non-CCD
generated mutations were found in the NTD, and intriguingly one of them, K14R has
been implicated in associating with LTR DNA during catalysis [132]. This mutation in
isolation did not improve the fitness of the parental virus (IN 269), but in combination
with the C56Y mutation facilitated enhanced replication kinetics, though not above the
C56Y mutant alone. The role of the other detectable subpopulations that were detected
outside of the IN reading frame are not known at this time. The vpr mutation that opened
the reading frame (Table 1), extending the protein by 12 aa is provocative, but the
overlapping substitution mutation in tat may be the more consequential mutation.
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Likewise the detection of an alteration of the tat splice acceptor may have ramifications
for replication. These mutants need to be tested in the future.
Though the vpr-vpu+ founder virus did not yield any compensatory mutations
within the IN reading frame, the mutations that did accrue were nonetheless instructive.
The loss of the vpu gene highlights the preferential mode of transmission within the CEM
cell line. We also detected another mutation that overlaps with the highly conserved AG
dinucleotide that controls the 3’ splice site for tat. Given Tat’s role in the transcriptional
activation of the viral LTR, it is likely that an enhancement of viral transcription,
comingling with the loss of Vpu function is sufficient to replicate a state in which virus
production crosses the threshold required to produce syncytia in an efficient fashion. The
impact of the tat splice acceptor mutation needs to be taking into consideration, if just to
observe whether that tat spliced message is upregulated in these viruses.
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A.

B.

Figure 36. Location of mutated residues in revertant virus culture. The dimeric
structure of IN, as solved by Stroud et al. [124], is depicted as a ball and stick model,
with the CTDs extended away from each other, and the CCDs providing the dimeric
interaction. The second-site revertant mutations are shown in space fill in one of the
yellow monomer, the C56Y and I60T mutations shown in purple. Note that in the
structure, Cys 56 was mutated to Ser. The catalytic triad is shown in red, and R269 on the
CTD proposed to hold the viral DNA for the yellow monomer is shown in green. (B) is
rotated 90° horizontally from the (A) view.
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Development of Non-overlapping IN-VIF ORF Virus

With the exception of EIAV, which does not encode a recognizable vif gene, a
universally-shared feature of the lentivirus genome is an overlap in the pol(in) and vif
ORFs (Figure 37A and B). It is perplexing that HIV-1, so dependent on its genomic
plasticity to elicit variants that evade immune responses, would adopt a genetic
organization that encumbers the independent evolution of its gene products. The tail of
IN, encompassed in the region of the overlap, is a relatively well-conserved region of the
CTD, in part due to the restriction imposed by the overlapping N-terminus of Vif. Indeed,
this region of Vif has been noted for its role in defining interactions with discrete
APOBEC family members. We sought to create a virus in which the reading frames of
pol(in) and vif are distinct, thus providing the flexibility to manipulate the IN tail without
simultaneous and unintentional Vif perturbation. The ultimate goal is to use these viruses
to evaluate the requirements of the IN tail during infection of primary CD4+ T cells and
macrophages, natural targets of HIV-1. Since these cells are Vif non-permissive, this
virus would be a useful tool that would allow manipulation of the IN tail without
disturbing the integrity of the vif gene or its product.
We created three related constructs that separated the pol(in) and vif reading
frames (Figure 37C). In each, the native nucleotide sequence of the IN tail, starting with
D270, is altered such that the third nucleotide of each codon triplet is replaced with a
synonymous base pair that maintains the natural IN amino acid sequence. The alteration
of the IN tail sequence in these constructs serves two purposes: it removes the natural vif
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ATG initiation codon from the IN reading frame, and it avoids the juxtaposition of two
identical sequences, a direct repeat that would likely be unstable with a propensity to be
removed by recombination. This original construct as just described is designated INVIF. Two iterations of this original construct were made, that may enhance the efficiency
of Vif protein expression. The first, called IN-VIF [IN(M275V)], substitutes the
methionine residue at position 275 in IN with valine, a naturally occurring polymorphism
found at this position.. In HIV-1, Vif is produced by alternative splicing of the viral
mRNA; the 3’ splice site controlling its expression lies just upstream of the natural
initiation codon of the vif gene. In our construct, this modification of IN M275V residue
makes the ATG initiation codon of vif the first ATG encountered by the ribosome on the
spliced transcript, thus increasing the efficiency of its translation. The second construct
iteration is called IN-VIF [VIF (KOZAK)]. In this construct, the four bases preceding the
vif initiation codon are altered to a canonical Kozak sequence (CACCATGG), which
would likewise enhance the efficiency of translation initiation at this ATG codon,
underlined in the sequence above.
We tested the above viruses for replication competency first in immortalized cell
lines. We selected both a permissive (CEM), and non-permissive (MT-2) cell line for
these initial experiments, observed the infected cell for the formation of syncytia, which
is indicative of productive infection (Figure 37D).
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Figure 37. Separation of the Pol and Vif reading frames allows for the independent
study of residues at the C-terminus of IN. A) Reading frames of HIV-1 depicted as
blocks. (B) Expanded view of the overlap sequence between IN and Vif. C) Mutagenic
separation of the reading frames. gTG (M275V) and cacc (KOZAK) are alternative
mutations constructed to facilitate Vif expression in IN-Vif virus. D) Results of syncytia
formation assay in Vif-permissive (CEM) and Vif-nonpermissive cells (MT-2).
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ResultsThe results are presented in Figure 37D. The IN-VIF constructs each created
syncytia at a comparable rate with the WT overlapping reading frame virus. Only the
[IN(M275V)] virus showed a slight delay in syncytia formation.

Investigation of Vif protein production:
Replication in the non-permissive MT-2 cell line indicated that our viral
constructs produced sufficient amounts of IN and Vif proteins that are required for
productive infection. However, the expression of a subset of HIV-1 genes, that include
Vif, is dependent on an optimized pattern of alternative splicing of the full-length viral
mRNA. Manipulating the viral genome has the potential to disrupt the delicate balance of
splicing, which can have global consequences on the expression of viral proteins. The
region that we manipulated lies just downstream of the pair of 3’ and 5’ splice sites that
facilitate the production of the vif-encoded spliced mRNA when the 5’ slice site is
suppressed. The organization of these sites in relation to the pol(in) and vif reading
frames are shown in Figure 38. This organization of splice sites is a common feature in
the HIV-1 genome, and confers a level of control over the production of the late viral
gene transcripts. For example, at some frequency a sub-optimal downstream viral 5’
splice site can be over-utilized, thus bypassing the downstream viral ORF coordinated by
utilization of the 3’- and suppression of the 5’-splice site, Conceivably, the over- or
under-activity of either splice site would affect not only production of that protein, but
that of downstream proteins as well. We investigated the levels of Vif protein production
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in the IN-VIF viruses to determine if Vif was being produced in natural amounts. Cells
were transfected with the various constructs, lysed, and then probed for vif protein
content. The results are shown in Figure 39.

Figure 38. Splice site organization for HIV-1 Vif reading frame. Transcription of the
viral genome starts at the boundary of the R region in the 5’ LTR. Splicing occurs
between the HIV-1 Major Splice Donor (MSD) and downstream splice sites that lie
upstream of the all HIV-1 regulatory proteins, and for Env. At some rate, a 5’ splice site
downstream of the 3’ splice site is utilized, bypassing the downstream ORF of the
protein.
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Vif

Figure 39. Investigation of Vif protein production in IN-VIF viruses. 293T cells were
transfected with the various constructs, lysed, and the cellular extracts were probed for
Vif protein content by Western blot analysis. The double bands observed for Vif is
attributed to the utilization of a downstream ATG codon in the Vif ORF that creates a
slightly shorter version of the Vif protein.
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ResultsAs shown in figure 39, whereas the Vif protein expressed from the WT plasmid is
undetectable over the background, the separated reading frame viruses IN-VIF and INVIF KOZ express an overabundance of Vif. The basis for this disruption might be
attributable to disregulation of the vif 3’ splice site. This was investigated.

vif Gene Splicing:
We next tested the levels of the vif splice product in transfections of our three
viral constructs. Total RNA was harvested, reverse transcribed and then subjected to PCR
analysis with a primer pair specific to vif or to the downstream vpr splice mRNA species
acting as a control for these experiments (Figure 40). The results show that compared to
the WT virus, the IN-VIF and IN-VIF [IN(M275V)]

viruses appear to be making

significantly more vif specific message, so much so that the vpr-specific primers are
preferentially detecting vif message over the vpr message. The IN-VIF [VIF (KOZAK)]
virus on the other hand has a more typical splicing pattern, and most closely resembles
the splicing pattern seen in the WT.
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Figure 40. Qualitative PCR of Vif and Vpr spliced products in IN-Vif separate ORF
viruses. Cells transfected with each virus construct were harvested for RNA, which was
reverse transcribed, and Vif and Vpr specific primers were used to detect the levels of Vif
and Vpr spliced messages.
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Primary Cell Infection:
These constructs were used in a preliminary experiment to see if they would
infect primary cells. The cells used for this experiment were CD4+T memory cells,
obtained by negative selection over a magnetic column, and activated with
phytohemagglutinin (PHA) prior to infection. The cultures were followed for several
days, and culture supernatant was assayed for the presence of p24 antigen at regular
intervals. The results are shown in Figure 41.
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Figure 41. Replication of IN-VIF virus in primary cells. Memory CD4+ T cells were
stimulated with PHA one day prior to infection, and challenged with WT virus, and INVIF virus. As a control, unstimulated CD4+ cells (WT no A) were infected with the WT
virus. Viral replication was followed by measuring p24 CA antigen released into the
supernatant. IN-VIF Virus-Dark blue; WT virus-Pink; Unstimulated cell infectionYellow.
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DiscussionThe IN-VIF separated reading frame viruses show great promise for use as a tool
for manipulating of the IN tail. Significantly, they are replication competent in primary
cell culture, and though the kinetics are somewhat attenuated, this signifies that the virus
can tolerate this genetic manipulation on at least the short term required for the planned
experiments. For our purposes, it may be necessary to initially passage the virus through
primary cells or a Vif non-permissive cell line to allow the virus to fine-tune itself for
enhanced fitness. The consequences of the massive Vif overproduction are not known,
but if it is detrimental it is possible that the serial passaging would repair the problem.
Furthermore, such experimentation will reveal whether several rounds of replication of
our manipulated genomic architecture can be tolerated by the virus.
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CHAPTER 4- DISCUSSION
Unique biochemical activities are often compartmentalized to distinct domains in a
single polypeptide chain, enabling an enzyme to orchestrate a particular biological
process. The elucidation of the domain repertoire of HIV-1 IN engendered the application
of such reductionist analyses, with attempts by many researchers to reconcile inherent
biochemical activities of isolated domains with the obligatory requirements of the
integration reaction. It quickly became clear, however, that when applied to IN this
simplistic allocation of specific activities was inadequate. Instead, a picture has emerged
in which each domain is implicated in contributing cooperatively to the requisite DNA
binding and protein-protein interactions in the minimally functional integration complex,
or intasome. The architecture of the HIV-1 IN-DNA complex is still a matter of
conjecture, and awaits the resolution of the structure of HIV-1 IN complexed with its
viral and target DNA substrates. Thus, the critical contributions of each domain can only
be inferred empirically from other sources.
The above considerations however fail to take into account the secondary roles of
HIV-1 in the viral life cycle. In the context of GagPol, IN influences the assembly
process by providing an integral but as yet, ill defined role in the regulation of precursor
processing. In addition, during the infection of target cells, IN contributes to the
efficiency of reverse transcription. This aspect of IN biology has been a source of
frustration in the field, for conventional dissection of protein function by directed
mutagenesis studies must always be considered with the potential simultaneous
disruption of primary and secondary functions in mind. Because of this, in vitro studies of
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IN functions, though critically insightful for studying facets of IN catalytic activities,
provides only a small view of the breadth of the activities attributable to IN in vivo. This
thesis describes a survey of IN CTD truncations aimed at deciphering the role of the IN
C-terminal tail, and by extension, the involvement of the entire CTD in the context of
viral infection. Most queries of mutant function I describe examine events at positions
within the life cycle in which IN is known to be an active participant. This includes posttranslation of the Gag and Gag-Pol precursor polyproteins, virion maturation and its
egress in the producer cell and those steps in the target cell that lead to the establishment
of the proviral state. Appraisal of replication defects associated with IN functionality
were dissected using a combination of novel and conventional methodologies, aimed at
uncovering the specific activities lost by specific CTD truncation. This information
provides a framework for follow-up focused investigations of IN activities in vitro,
settings that can suitably eliminate confounding variables from consideration.
During the preparation of this dissertation, the highly anticipated crystal structure of a
retroviral integrase in complex with its substrate DNA was solved to high resolution
[199]. Although the structure is derived from the distantly-related prototypical foamy
virus (PFV) IN, the potent susceptibility of the enzyme to the current INSTI drugs makes
this achievement particularly relevant to the HIV-1 IN field. From the standpoint of
previous theoretical models, the data divulges a wholly unanticipated arrangement of
individual subunit domains within monomeric IN and subunit arrangement within the
tetrameric intasome. Nonetheless and in agreement with an inferred consensus gleaned
from the plethora of HIV-1 IN studies, each domain in the PFV IN structure contributes
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to both protein-DNA and protein-protein contacts. Though it is presently unknown
whether the extrapolation of the structural arrangements of the PFV intasome onto that of
HIV-1 is correct in all of its manifestations, wherever possible, our results are interpreted
below in light of this new structural model.
Three-dimensional information for the HIV-1 IN CTD abruptly ends at Asp 270,
the ultimate residue of an interwoven mesh of 5 interconnected β-sheets spanning 48
amino acid residues. The overall topology assumes an SH3-like fold, to which is
appended the final 18 residues constituting the disordered tail. PFV IN likewise contains
a disordered tail of equal length, recalcitrant to structural resolution apparently due to a
high degree of flexibility. One concern of the potential consequence of sequential
removal of residues past the 270 boundary and into the structured region is the disruption
of intimate inter-β-sheet interactions that sustain the three-dimensional structural integrity
of the SH3-like element and the CTD. Some of our observations certainly hint that such a
situation might be occurring by truncating past IN 268. Although IN 268 is a replicationincompetent Class II viral mutant, its behavior in several assays reflects the preservation
of a nominal IN activity that is lacking with further truncation. Indeed, removal of amino
acids past Ile 268 (i.e. IN 267, 266, 265, 260) creates a mutant class that behaves
remarkably similar to a mutant that is completely devoid of the CTD (IN 212), in terms
of intracellular processing, virion Gag-Pol packaging and in their ability to complement a
CCD catalytic mutant (D116A). Furthermore, the eGFP-IN 267 fusion protein creates
large cytoplasmic aggregates (Figure 32), a behavior described for misfolded proteins.
Although IN 267 and IN 268 both terminate in hydrophobic Ile, the eGFP-IN 268 fusion
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protein appears to function normally by interacting with LEDGF, and apparently not
disposed to aggregation. This may hint that the Ile 268 residue is participating in its
appropriate context. Paradoxically, the eGFP-IN 266 fusion protein terminating in
Lys266 does not aggregate, a result that may indicate that if solvent exposed, Lys266
may favor solubility of the protein. Taken together, the intermediate behavior of the IN
268 viral mutant, its length just one amino acid short of replication-competent IN 269,
suggests that Ile268 could represent the final “nail” holding and maintaining at least a
portion of the SH3 fold. In fact, the NMR structural data for HIV-1 IN CTD in solution
reveals that Ile268 is the last residue of the fifth and final β-sheet (residues 265-268) of
the SH3 fold. Close inspection of the NMR structure indicates that Ile268 is in intimate
contact with Phe226 in a proximal β-sheet. This interaction contributes to the
establishment of a bridge of hydrophobic interactions encompassing the three sheets (β 1,
β 2 and β 5) across one face of the fold (Figure 42).
If our assertion of disparities in CTD integrity is accurate, then the
complementation studies of the IN truncation panel support current mechanistic models
for the HIV-1 integration reaction. Numerous studies support a model in which each viral
cDNA end is processed by an IN dimer that likely assumes the orientation discovered in
the HIV-1 IN crystal structure, depicted in Figure 36. The authenticity of the dimer
interface, created by vast CCD-CCD contacts, is supported by the presence of this
identical interaction in the PFV intasome structure. The physical separation of the CTD
domains is due to an asymmetry between the two monomers created by a kink in the
CCD-CTD α-helical linker in one subunit. The viral cDNA is proposed to interact with
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the IN dimer in such a way that the end of the DNA molecule lies in the catalytic core of
one subunit, while the DNA molecule extends away along the outer aspect of that subunit

Figure 42. Hydrophobic interactions in the SH3 fold of the IN CTD. The SH-3 fold of
the IN CTD displayed with beta sheets 1, 2a and 5 in blue, and 2b, 3 and 5 in ochre. The
side chains of the three hydrophobic residues making putative interaction are shown in
stick model.

to then establish an association with the CTD of the second monomer. In this way, the
CTD of one subunit stabilizes the DNA, while the opposed subunit conducts the
enzymology that directs 3’ processing. This premise forms the basis for our model
(Figure 43) proposed to account for our observations of the IN truncation
complementation. IN 267, for example, contains a catalytically-active CCD, which
according to the model can be supplied in trans to the IN D116A mutant, which
reciprocally supplies an intact CTD, thus satisfying the requirements for processing. If
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what we assert is accurate, then although IN 267 has an improperly folded CTD,
processing can proceed because of the particular arrangement of IN molecules during
processing. This complementation is what was observed in both IN 266 and IN 267 viral
complementation experiments (Figure 30B). In contrast, strand transfer is coordinated by
at least a tetrameric assembly of HIV-1 IN monomeric/dimeric units and is thought to be
contingent upon completion of the previous catalytic step (3’ processing). Indeed, the
tetrameric assembly of PFV IN on its pre-processed DNA substrate used for
crystallization studies provides very strong evidence for such a premise. Unlike the
dimeric IN unit, which relies solely on CCD-CCD interactions, it is believed that the
HIV-1 IN tetramer, like that of PFV IN, is stabilized in part by protein-protein
interactions facilitated by the CTDs from distinct dimeric units. Thus, despite achieving
relatively significant levels of processed DNA ends, loss of the essential contacts
required to create the tetrameric strand transfer complex may preclude the second
integration step. This is reflected experimentally in the relatively poor integration rate of
the hybrid IN 267/IN D116A virus, in spite of rather efficient processing at each of the
viral DNA ends (Figure 30 A and B). IN activity however extends beyond integration,
and the unique behavior of the IN 268 was evident also in its intracellular processing
profile. Indeed, the addition of Ile 268 (IN 268) did not fully rescue the processing
defects of the Class II IN truncation mutants, but it did significantly alter the processing
of the Gag-Pol polyprotein precursor, establishing a semblance of the WT pattern. Our
data suggest that the altered pattern of precursor processing observed for the Class II
mutants was precipitated by disregulated viral protease activity. Though the mechanisms
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Figure 43. Model for the complementation of CTD truncation mutants. IN D116A
possesses no catalytic activity, but is functional for all other aspects of the viral life cycle.
Significantly, it possesses an intact CTD domain, which is the deterrent for the IN CTD
truncations. In the first iteration, if two D116A monomers associate, 3’ processing does
not occur due to both monomers lacking a catalytic site. The IN truncations, for example
IN 267, possesses an intact catalytic site, but the disrupted CTD can no longer function to
stabilize the DNA in the catalytic core of its opposing subunit. When IN D116A and IN
267 associate however, the intact CTD of the IN D116A subunit can successfully supply
in trans that activity that is inherently missing from IN 267, and so processing can
proceed. The strand transfer reaction however is thought to require at least a tetrameric
arrangement of IN molecules held together partly by CTD interacts. The disrupted CTD
of IN 267 does allow some strand transfer to occur in the context of the hybrid IN D116A
virus, but not as efficiently as other viruses that support a similar level of 3’ processing
(IN 269, Figure 30)
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underlying viral protease activation are unclear, studies indicate that dimerization of the
Gag-Pol precursor is a necessary prelude, since the active site of the viral protease is
comprised of two individual protease subunits [49]. In vitro studies indicate that the
initial cut made in the Gag-Pol precursor by the activated protease occurs at a predestined
cleavage site in the precursor dimer, usually at the p2 spacer/NC junction [189]. The
subsequent precursor processing ensues in an ordered and temporally staggered fashion
until full processing is accomplished. A perhaps significant observation is that the PR
embedded in Gag-Pol can efficiently cleave only a limited set of protease sites, whereas
the mature PR is capable of efficient cleavage at all sites [189].
It has been noted previously that limited IN CTD truncation or its complete
ablation leads to premature precursor processing, but the mechanistic details have not
been fully explored. While one possible explanation is that the CTD in the Gag-Pol
context could deter precursor dimerization, we observe a large quantity of intracellular,
partially processed products in the WT virus, indicative of precursor dimerization leading
to initial PR processing. Naturally, the tissue culture system in which we are studying this
phenomenon is artificial; in vivo infections likely cannot support the extent of viral gene
production that is possible from a transfection of highly competent HEK 293T cells.
Consequently, the levels of Gag-Pol in a natural setting would not likely achieve levels
high enough to possibly accelerate intracellular dimerization. An alternative mechanism
for role of the CTD in processing is that it may influence the selection of initial cleavage
sites of the embedded PR concomitant with Gag-Pol dimerization, thus directing a pattern
of cleavages that precludes the production of mature protease at early time points. The
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Western blot in Figure 27 seems to indicate this very proposition, as there is a clear
difference in the cleavage pattern of IN 266 and 267 in the presence of Ritonavir. Studies
have shown that the embedded PR is up to 10,000x less sensitive to Ritonavir than the
mature PR, and this phenomenon has been used to dissect the initial cuts made by PR
concomitant with precursor dimerization [49]. One can envisage a number of
mechanisms by which this could occur, including physical occlusion of protease sites by
the IN CTD, or by a direct interaction of the CTD with the PR domain, or alternatively
with the RT domain, a region of Gag-Pol implicated in facilitating the dimerization of
Gag-Pol precursors [47, 171]. Alternatively, the CTD could recruit cellular proteins that
could influence PR activity. One such candidate is Integrase Interactor 1 (INI1/hSNF5),
an identified cellular binding partner that binds IN within the context of Gag-Pol and is
packaged into virions [174]. The intriguing aspect of this interaction is that if it is
abrogated, the viral infectivity is blocked at the late stage of replication, during assembly
[174]. The CTD of IN has been implicated in facilitating the binding of several other
cellular proteins, and future studies of the interaction capabilities of our IN CTD
truncations with known cellular binding partners may prove fruitful.
IN 268 is nonetheless a Class II mutant, unable to support RT activity. It is also
apparent that the defect in its CTD also blocks its ability to conduct the integration
reaction, based on our experiment with IN 268 and the Class I IN 270 experiment.
However, we find that IN 269 to be replication competent, indicating that at this CTD
length, IN is possessed of not only its primary integration activities, but also by necessity,
all of its ancillary functions. Indeed our data demonstrate that IN 269 virus exhibits
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accurate intracellular processing and efficient reverse transcription, abilities both lacking
in the IN 268 mutant. The arginine residue at 269 has however not been implicated as a
particularly critical CTD residue. In the context of the full-length protein, an R269A
mutant is replication competent, albeit with significantly delayed kinetics, and was
classified tentatively as Class I to indicate that the defect was specific for integration [2].
So, in light of the significance of the R269 residue for IN catalysis, and not for reverse
transcription, our data suggests that the sudden gain of secondary IN functions for IN 269
for both the precision of Pr55Gag and Pr160Gag-Pol processing and RT activity is not due to
the sudden acquisition of specific interactions per se, but is more likely explained by an
enhanced stabilization of the SH3 fold that is induced by inclusion of this residue. Indeed,
recent reports describing a functional IN/RT interaction mapping to the IN CTD [109,
110, 148, 149] and plasma resonance analyses [148] identifying specific CTD residues
mediating the RT interaction did not include R269 among the specifically interacting
residues, highlighting an indirect role of this residue in promoting reverse transcription.
With the gain of normal, albeit diminished function in IN 269, and our assertion
that the R269 residue might enhance CTD stability in the context of the truncated protein,
we were surprised to find that the addition of the subsequent one to three residues results
in a loss of replication competency (mutants IN 270, 271 and 272). The loss of
replication status of these particular mutants is not likely due to the misfolding of the
SH3 fold, as the late RT and complementation experiments suggest that it is probably
intact. These IN mutants advance through the preceding viral life cycle stages with
minimal defect but are defective specifically for catalysis, demonstrated by a lack of viral
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3’ end processing. Our data thus suggests that a correctly folded and intact SH3 fold
sufficiently facilitates the secondary IN functions (precision of processing, RT activity),
but more is required for integration itself. What component of IN catalytic activity
necessary for the integration reaction itself is lost by adding one, two or three additional
residues to IN 269? Given that 3´ processing is affected, it is feasible that the appendage
of the one, two or three residues corresponding to IN 270, 271 and 272 to the IN 269
mutant curtails the CTD-viral DNA binding required for stabilization and positioning of
the DNA end in the active site of the opposing IN subunit in the integrase dimer. The
addition of a single residue at 273, an invariant residue subject to both acetylation [3, 4]
and possibly ubiquitination [153], rescues infectivity. Though it has been suggested that
the K273 plays significant roles in integrase dynamics, including specific DNA binding,
substitution of alanine (K273A Stop) or arginine (K273R Stop) instead of the natural
lysine residue to the truncated protein is still sufficient to rescue integration activity to
high levels (data not shown). Further biochemical analysis of these Class I truncations is
required to determine the specific activity lost by addition of these additional residues to
IN 269.
The function of the tail is still unknown after this work, but it is clear that it
enhances both secondary and primary IN functions. For the precision of precursor
processing, the contribution of the tail is clearly evident when comparing IN 282 and IN
288 (full-length) (Figure 26, lanes 16 and 17 and Figure 28, lanes 18 and 19). There was
however, no indication that the tail enhanced the efficiency of RT activity (Figure 18).
For primary IN function, the contribution of the tail is evident during the first step of
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integration, 3’ processing (Figure 24), with a gradual improvement of processing
efficiency with incremental lengthening of the tail. From our data however, we cannot
determine why this should be so. If the IN dimer model for the processing reaction is
accurate, then the tail might serve to augment the affinity of the CTD for the viral DNA,
making it better suited to lock the DNA in position for 3’ processing at the distal end of
the DNA molecule. Too short a tail (IN 270, 271, 272) is detrimental, perhaps a
hindrance for productive DNA binding. A longer tail then may be increasingly flexible
and capable of holding and locking viral DNA in place.
Selection for second-site revertants evolution experiments identified two
mutations that significantly increased the integration efficiency of the tail-less mutant
(C56Y and I60T), both of which, when using conventional domain boundary
designations, map to the CCD (aa 50-212). Close inspection of the solved HIV-1 IN
NTD/CCD two-domain structure however reveals that the precise location of Cys 56 is
within an unstructured linker sequence between the NTD and CCD, whereas Ile 60 is at
the boundary of the linker and the CCD, representing the initial residue of the first
structural element within the CCD. Comparisons of the related residues in PFV IN reveal
a provocative role of these particular residues in the assembled IN-DNA complex. The
PFV intasome was assembled with a preprocessed DNA substrate, and intriguingly PFV
IN Ile 112, the residue equivalent of HIV-1 IN C56 from structure-based alignment of the
two proteins, comes into intimate contact with the thymine base of the fifth nucleotide in
the unprocessed DNA strand. This nucleotide position is the first in the DNA substrate to
conform to a double-stranded structure; the terminal five nucleotides of the unprocessed
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strand are single-stranded and bent away from the complementary strand. Ile112 may
thus play thus be involved in DNA binding and positioning in the active site before or
during processing, and/or facilitating distortion of the DNA helix, which in combination
with DNA end fraying is required for 3’ processing [200, 201]. It maybe premature to
make direct comparisons of the two enzymes, especially taking into consideration the
differing lengths of the NTD-CCD linkers in the two proteins, but such a mechanism of
enhanced binding or distortion of the viral DNA in the active site may explain why the
C56Y mutant can rescue a purported DNA binding attenuation by the truncated IN 269
CTD.
In spite of lingering uncertainty of the actual mechanism by which the tail
contributes to the integration reaction, it is apparent that the activity it exerts is most
essential at 3’ processing, and not for the subsequent strand transfer. Indeed, for the tailless IN 269 mutant, and for the panel of truncations as a whole, the limiting step for
transduction ability is 3’ processing. Once the ends are processed however, the viral
DNA is expeditiously and very efficiently integrated, indicating that strand transfer is not
affected by the absence of the tail. This assertion is supported by the value of the
integration rates of the tail-less virus, relative to the 3’ processing levels (Table 3). This
analysis indicates also that the second-site compensatory mutation improves the
replication dynamics of the virus specifically for 3’ processing. The subsequent strand
transfer step actually appears to proceed somewhat less efficiently, when compared to the
parental 269 stop virus (Table 3).
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Table 3. Efficiency of tail-less IN viruses to complete strand transfer after
processing viral DNA ends.

MUTANT

LATE RT

3'Processing/late
RT
(%WT)

C56Y 269 stop
I60T 269 stop
269 stop
WT

117.2
129.7
307.8
100

42.9
38.0
8.9
100

Frequency
of
Integration
(%WT)

Freq Int/3'
processing
(%WT)

58.6
58.2
24.2
100

136.6
153.2
273.0
100

These considerations serve to further solidify the important role of the tail during
3’ processing. Unfortunately, the solved intasome structure of the PFV does not divulge
any pertinent information regarding the subunit arrangement of IN for 3’ processing,
since the complex was assembled with preprocessed DNA substrate, and as such is
primed for strand transfer. In the PFV IN-DNA complex, a pair of asymmetric IN dimers
come together to form the tetrameric complex. The inner subunits of the tetramer
contribute all of the contacts involved in DNA binding and tetramerization, whereas the
outer subunits, of which only the CCDs could be resolved, are postulated to contribute a
supporting function. In current models of the HIV-1 integration, it is these outside
subunits that provide the necessary CTD contacts on the viral DNA for the 3’ processing
reaction, in which the functional catalytic unit of IN is the dimer form. In the PFV
structure, the NTD and CTD structures were not resolved in the outer subunits of the
tetramer, and the apparent lack of contribution of these domains from the outer subunits
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to the strand transfer complex is further proof of a function of the IN tail that is useful
for processing, but subsequently unnecessary for strand transfer.
If the HIV-1 intasome does in fact assume a similar conformation to that of the
PFV, then examination of the PFV crystal structure could reveal why certain truncations
cannot be efficiently complemented for the strand transfer reaction. It is established that
the IN subunit that performs 3’ processing subsequently catalyzes the strand transfer
reaction. Therefore in the observed complementation of the IN 266 and 267 with D116A
for 3’ processing, the truncated subunits are thus positioned as the internal subunits that
will conduct the strand transfer reaction. The structure of the PFV intasome reveals that
the CTD of one inner subunit is positioned between the CCD and NTD (Figure 44) where
it interacts with both inner subunit CCDs and the phosphodiester backbone of both viral
DNA molecules, thus serving to crosslink the two dimers. Intriguingly, the His 377
positioned at the end of the CTD SH3 fold comes into intimate contact with Val 93 in the
NTD (Figure 44B). Also, the Ser 376 established Van der Waals interactions with the
phosphodiester backbone of the unprocessed strand in the second DNA end [199], not
depicted here. Thus one can envisage removal of these two residues from the extreme
CTD terminal end could destabilize this region of the complex, leading to detrimental
strand transfer.
In the past, analyses of IN truncations have been conducted, but to our knowledge
never with the single amino acid resolution as presented here. A recent study of IN CTD
truncations was reported, but the mutagenic survey was conducted at intervals of three to
four residues, thus by-passing the IN 269 mutant for description [202]. Also our Class I
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designation of the IN 270 truncation is in disagreement with their Class II assessment for
this particular mutant. We do however observe and concur that the CTD tail is not
critical for viral replication, apparently enhances both secondary and primary integrase
functions with effectiveness concordant with its length. The functional boundaries within
the CTD for specific IN activities and contributions to viral dynamics in the context of
infection have been identified (Figure 45), and can be used as a stepping stone to further
characterize IN primary and secondary roles. Studies of the IN 268/269 boundary for
instance might provide insight into the poorly understood dynamics of precursor
processing, and the mysterious role for IN in the context of within these processes. Also,
by virtue of its complete lack of the unstructured tail, the enzymatically-active IN 269
mutant is the ideal tool for deciphering the contributions of the C-terminal tail to IN
functionality. In this regard, uncovering the specific defect/s of IN 270, 271 and 272 will
also provide a clearer picture of the role of the tail, and of the domain as a whole. These
lines of inquiry will provide a more comprehensive knowledge of IN and its diverse roles
in viral replication, which then lays a foundation for the potential development of multipronged therapeutic interventions that neutralize IN not only at integration, but also in its
ancillary yet significant roles in other aspects of the viral life cycle.
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Figure 44. Interactions of the PFV CTD within the intasome may give insight into
HIV-1 CTD truncations. A) The CTD (green) of the PFV IN lies between the NTD
(blue) and CCD (brown) in the tetrameric intasome, establishing contacts with both viral
DNA ends, and contributing protein-protein interactions with the opposing subunit. One
dimeric subunit is shown here. The monomer (gray) not participating in DNA contacts
was only resolved for the CCD, the NTD and CTD remaining unresolved in the structure.
The CTD participating in the reaction is colored green, and contacts both the viral DNA
(yellow and pink ball and stick) and the NTD of its own subunit (blue). B) A close-up of
the interaction between the very end of the CTD (His 377) with Val 93 in the NTD. The
pertinent residues are shown in space-fill.
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Figure 45. The properties of IN bestowed by increasing CTD length. A summary of
the reported findings of the properties of IN at various CTD lengths.
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CHAPTER 5- FUTURE STUDIES
ROLE OF LEDGF IN 3’ PROCESSING
The association of HIV-1 IN with the LEDGF/p75 co-factor is one of the most
well characterized interactions at the virus/host molecular interface. The predominantly
nuclear LEDGF/p75 has been demonstrated to be essential during the early stage of
infection, specifically at integration, asserting its effect by direct binding to IN. Despite
the intensity of research, some ambiguity concerning the role of this protein in facilitating
integration activity still exists. It has been suggested that its karyophilic properties may
assist in PIC nuclear import, or that its action as a molecular tether targets IN to the
chromosome by simultaneously binding chromosomal DNA and IN. In vitro, LEDGF
enhances integration activity, and increases the solubility of recombinant IN. Several
lines of evidence indicate that LEDGF binds a tetrameric form of IN, and so enhances the
efficiency of concerted integration. LEDGF may thus also play a role in stabilizing IN
complexes, functioning as a molecular chaperone to ensure the accurate assembly of IN
oligomers required for integration, and by preventing the formation of higher-order nonproductive aggregations of IN.
An additional element of uncertainty addresses the point at which LEDGF first
encounters IN during infection, whether the interaction is first established in the nucleus,
or in keeping with a role in nuclear import, within the cytoplasm. In one study, LEDGF
was found as a component of cytoplasmic PICs in acutely infected cells [198] and thus
the protein may in fact play a role in events occurring prior to or during nuclear import.
The contribution of LEDGF to the 3’ processing reaction is unclear, but its presence in
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the PIC indicates that it could influence this first half of the integration reaction. The
quantitative 3’ processing assay we developed allows the opportunity to study the effect
of LEDGF on viral DNA processing in vivo, by using cell-lines that stably express
shRNAs that abolish LEDGF production. Though it is currently believed that a dimer of
IN conducts the processing reaction at either end, a tetrameric model cannot be
discounted. These experiments might thus illuminate both the role of LEDGF during
HIV-1 infection, and the multimeric form of IN during the 3’ processing reaction.

ORF VIRUS
The IN-VIF separated reading frame viruses have to this point only been
preliminarily tested for replication competency. Though we found that these viruses
replicated rather efficiently in primary cells, our manipulations have clearly disrupted the
delicate balance of viral transcript splicing. The repercussions of this imbalance are
unknown, but any effects, innocuous or not, detract from the validity of this virus as an
investigative tool for deciphering the role of the IN CTD tail. We thus intend to seriallypassage the virus through Vif non-permissive cells, to allow for the selection of fitnessenhanced viral variants that have presumptively fine-tuned the aberrant splicing program,
plus any other defects we may have overlooked. The resulting virus then can be used for
investigating the contribution of the tail in primary cell cultures of the natural targets of
HIV-1, primary CD4+ T cells and macrophages, which require Vif function, and in which
there may be a stricter and more discernable requirement for the IN tail.
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The architectural manipulation of these viruses will permit investigation into the
contribution of the lysine at position 273 in IN to viral dynamics, a residue found to be
potently acetylated, and possibly subject to ubiquitination. The location of this residue in
the ORF overlap between pol(in) and vif has hindered the investigation of these
phenomena by mutational studies in primary cells due to the potential alteration of Vif
protein function. The role of acetylation of IN is currently unclear, but given the
divergent activities of the CTD in DNA binding and protein-protein interaction, it is
intriguing that this domain is subject to a posttranslational modification known to
modulate several aspects of protein function in a variety of systems.

DECIPHERING THE CONTRIBUTION OF THE C56Y AND I60T MUTATIONS
The second-site mutations C56Y and I60T enhance the efficiency of integration in
the context of a tail-less IN, but the mechanism by which they do so has yet to be
determined. Establishing the roles of these residues in the context of the integration
complex would by extension illuminate the function of the tail during integration. To this
end we will first ascertain the specific context of the compensatory mutations within the
IN assembly that conducts the 3’ processing reaction. Our model for the events occurring
during processing (Figure 43) stipulates that the contribution of the second site mutations
would only be relevant within the IN subunit that actually conducts the processing. We
can verify this model by creating hybrid viruses containing a tail-less, catalytically
defective IN D116A (IN D116A 269 stop) and an IN 269 stop IN with either of the
second site mutations, and comparing these with hybrids that possess the second site
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mutation in both IN molecules. Similar kinetics of processing in both cases should
solidify that the basis for the rescued activity divulged by the compensatory mutations is
within the specific context of the catalytically-active subunit. Additionally, several other
combinatorial iterations of tail-less and full-length IN hybrid viruses can envisaged to
further investigate the organization of IN within the processing and strand transfer
complexes.
We postulated that the C56Y and I60T mutations might serve to rescue a DNAbinding defect that is wrought by tail truncation. We can test the DNA binding ability of
the various truncation mutants, with and without the compensatory mutations, using in
vitro systems to measure the affinity of recombinant IN molecules for viral DNA
substrate. We will also test the catalytic activities of IN molecules containing these
compensatory mutation using established in vitro assays for measuring 3’ processing and
strand transfer. Such experiments applied to the Class I IN mutants IN 270, 271 and 272,
which we believe are defective for DNA binding, may identify the specific defects of
these mutants.

PRECISION OF PARTICLE FORMATION
Precursor protein processing is initialized when Gag-Pol precursors dimerize,
leading to activation of the embedded PR, and an ordered pattern of internal cleavage
events within the precursor. The precursor processing behavior of the Class II IN
truncations observed in Figure 27 may be attributable both to enhanced dimerization,
and/or aberrant selection of initial PR cleavage sites that result in the premature and
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detrimental accumulation of mature PR in the cytoplasm. It is well established that IN
mutations and truncations can promote premature precursor processing, but the
mechanism underlying the role of IN within this process is obscure. Our observations of
the cleavage pattern of IN Class II mutants in the presence of high concentrations of
Ritonavir suggest that the initial cleavages of the Gag-Pol precursor might be altered, and
thus may account for the aberrant pattern of precursor protein products detected in these
mutants. To study this phenomenon, we can determine the precise sites of initial cleavage
of the viral precursor, by systematic substitution of a β-branched amino acid (such as
isoleucine) at the P1 position of various PR cleavage sites. The P1 position is the first
residue upstream of the scissile bond, and mutation of this position has been shown to
abolish PR cleavage [203]. The resulting discernment of an altered pattern of initial
cleavages afforded by incubation in high concentrations of Ritonavir will permit the
identification of the alternate sites that are utilized by the class II versus WT IN
truncations.

CTD INTERACTIONS WITH KNOWN BINDING PARTNERS
Several binding partners have been found to interact with IN via the CTD. These
include EED polycomb, p300, HIV-1 RT, Rad18 [3, 110, 146-148]. The ability of the
different truncations, especially in the IN 268 269 271 272 273 region will be tested for
differential affinities for interacting with these partners, via reciprocal pull-down
experiments or by microscopic techniques. The loss or gain of interaction may reveal the
significance if any of any of these controversial IN interactors.
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